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ABSTRACT 
 Unnecessary prescribing of antibiotics for viral respiratory tract infections is 
common and contributes to emerging antibiotic resistance and patient morbidity and 
mortality. Interventions aimed at promoting judicious use of antibiotics, such as 
prescribing guidelines, are often ineffective. Approaching the problem of overprescribing 
from new perspectives is key to making progress towards more effective antimicrobial 
stewardship. Exploring characteristics shared between patients and providers, attitudes of 
new antibiotic stewards, and the role of prescribing on subsequent use offer opportunities 
to better understand antibiotic stewardship and overprescribing at a time when new 
perspectives are needed to inform better interventions.  
 This dissertation contains three studies that incorporate novel perspectives to 
investigate the patient, provider, and practice factors that promote judicious use of 
antibiotics and solicit a better understanding of the current state of stewardship from 
future antibiotic stewards. Study 1, A Qualitative Study of the Knowledge and Attitudes 
of Infectious Disease Fellows, sought to understand the attitudes and beliefs of infectious 
		 vii 
disease fellows on the front line of antibiotic stewardship. Fellows highlighted the 
importance of formal and informal education, explained the challenges faced when 
practicing stewardship, and suggested improvements to fellowship programs to 
encourage better antibiotic stewardship training. 
 Study 2, Patient-Provider Race and Sex Concordance in Prescribing, explored 
how race and sex concordance between patients and providers predicted overprescribing. 
Results showed that racial concordance was one of the most important predictors of 
overprescribing, suggesting that concordance can be more important to the prescribing 
outcome than some clinical indicators and that improving cross-cultural communication 
may be a way to combat overprescribing. 
 Study 3, Early Prescribing Behavior as a Predictor of Future Antibiotic Exposure 
and Resource Utilization, described how the decision whether or not to prescribe 
antibiotics at a child’s first acute bronchitis visit affected that child’s likelihood of 
returning for an additional acute bronchitis complaint and being prescribed an antibiotic. 
The results of this study suggested that the prescribing behavior of providers can affect 
future visits and subsequent prescribing.  
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CHAPTER ONE: REVIEW OF THE RELEVANT LITERATURE 
Overview: The state of antibiotic prescribing 
Overprescribing of antibiotics is widespread, and continues to persist despite 
substantial research and efforts to improve practice (1–5). The consequences of 
overprescribing – prescribing an antibiotic when it is not clinically indicated – range 
from large community-level effects such as antimicrobial resistance or burdensome 
costs, to patient-level effects such as treatment failure, morbidity, and mortality (6, 7). 
Antimicrobial resistance in particular can have wide-reaching effects by making 
infections more difficult to cure in the future. Resistant bacteria such as Streptococcus 
pneumoniae resistant to penicillin and macrolides or Staphylococcus aureus resistant to 
oxacillin are increasingly causing community-acquired infections (8, 9). To better 
address the threat of antibiotic overprescribing and encourage judicious use of 
antimicrobial agents, this dissertation aims to understand how important patient, 
provider, and practice factors interact in the prescribing process and how this 
knowledge can be leveraged to inform more effective stewardship interventions.  
The need for stewardship 
Antibiotic stewardship efforts are crucial to protect the usefulness of lifesaving 
antibiotics and prevent increased patient morbidity. Overuse of antibiotics has been 
definitively linked to resistance, and pathogen resistance to an antimicrobial renders the 
treatment less effective or useless and can fail to cure the infection (10–18). In addition 
to resistance, overuse of antibiotics can have other negative consequences for the 
patient. Antibiotics can negatively affect the bacterial flora in the gastrointestinal (GI) 
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tract, triggering GI related side-effects (19). In adults, antibiotics can cause mild to 
severe diarrhea, particularly dangerous for the infirm or elderly, and when caused by 
the Clostridium difficile pathogen, can be life threatening (20). Children may 
experience additional side-effects, as they tolerate antibiotics differently (for example 
non-Clostridium difficile diarrhea happens in 50% of children exposed to amoxicillin-
clavulanic acid and is much less common in adults) (21). Compared to adults, the rate 
of overprescribing has fallen in pediatric populations thanks to effective interventions 
(22, 23). However, the rate still remains unacceptably high. The persistence of 
overprescribing and its detrimental effects create a need for more intensive antibiotic 
stewardship efforts to promote the judicious use of antimicrobial agents.  
Predicting overprescribing 
The first step in developing effective interventions to curb antibiotic misuse is to 
understand the prescribing process – what factors predict prescription of an antibiotic 
when it is not necessary. Previous literature has described many factors associated with 
antibiotic prescribing (24, 25). In this dissertation I focus on how better understanding 
the prescribing process and stewardship can present opportunities for innovative 
interventions. Specifically, I examine the role of patient and provider race concordance; 
explore how repeat visits influence, or are influenced by, antibiotic prescribing, and 
examine the attitudes and beliefs of infectious disease (ID) fellows towards antibiotic 
stewardship. A better understanding of these predictors can help inform the creation of 
customized, effective interventions. 
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Race and prescribing 
Numerous factors have been found to be associated with antibiotic prescribing 
in the literature, and the race of the patient is a common demographic control variable 
included in predictive models alongside other characteristics such as age and sex (26). 
The results of these studies have been mixed, where some found non-white patients 
more likely to be unnecessarily prescribed an antibiotic for a respiratory tract infection 
(RTI) (27–29), others found them to be less likely (24, 30–38), and some studies failed 
to find any association (25, 39–43). However, there has been very little discussion of 
why race was included, or what the association between race and prescribing means. 
For example, one study included race as an a priori variable of “clinical significance” 
but failed to explain why race was clinically important for antibiotic prescribing of 
acute RTIs and did not present the predicted effect of race on prescribing (44). More 
research is needed to understand the exact way in which race affects prescribing and to 
directly explore the reasons behind such an association.  
 The most common finding regarding patient race and prescribing in the 
literature has been that minority patients are less frequently prescribed antibiotics. For 
example, a study using data from the National Ambulatory Medical Care Survey 
(NAMCS), a nationally representative database of outpatient visits, examined trends in 
prescribing for acute cough in patients over 14 years (37). The authors found that white 
patients had 1.75 times the odds of receiving a prescription for an antibiotic compared 
to non-white patients, one of the larger effects in the predictive model (37). The 
authors, however, did not comment on the effect of race, noting only that “[t]he 
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association of certain patient characteristics with the increased use of antibiotics by 
primary care physicians suggests that there may be important nonclinical barriers to 
promoting more judicious use of antibiotics” (37). Previous research which has found 
that non-white patients are less often prescribed antibiotics for RTIs has been 
corroborated by single-site or regional studies in the South (36), the West (32), the 
Northeast (24, 30, 31), and the Midwest (30), as well as in other national-level analyses 
(33–35, 38, 45).  
On the other hand, there is also evidence for minority patients being more at risk 
for being overprescribed antibiotics, although this is less common in the literature. For 
example, one small study (n~500) found evidence that minority race led to more 
prescriptions, but in multivariable analysis only Latino and Asian parents had 
significantly greater expectations for antibiotics and the differences in actual 
prescribing rates failed to reach statistical significance (27). A second study was 
substantially larger, but based in Taiwan, where the minority group (Aborigine) may 
not be comparable to the U.S. (28). That study found minority patients had 1.09 greater 
odds of receiving a prescription for nasopharyngitis, upper RTIs, or acute bronchitis. 
Additionally, a larger study found that geographic regions with larger shares of black 
residents were more likely to have higher rates of antibiotic prescribing, but this study 
did not control for any other factors, such as region of residence which may have biased 
the results (29) (for example the South has a higher share of black residents and 
providers from that region have been found to prescribe more on average independent 
of patient race) (46, 47).  
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Finally, another group of research studies failed to find any relationship between 
race and prescribing. For example, a study combining NAMCS data with National 
Hospital Ambulatory Medical Care Survey (NHAMCS) data failed to find an 
association between race and prescribing of antibiotics in over 20,000 visits for acute 
respiratory infections (25). This finding was replicated in other studies with large 
sample sizes, including data from Veterans Affairs’ hospitals (40, 42) and nationally 
representative databases (43), as well as smaller, prospective studies (39, 41). Across 
these studies, the findings regarding the relationship between race and prescribing were 
mixed.  
Studies that included race grouped it with other patient characteristics and 
hypothesized that the effect may be due to differences in patient culture and patterns of 
health care use (24, 27, 35). Such differences included the patient’s expectations and 
the provider’s perceptions of patient expectations (24, 30, 32), language barriers (27), 
or that the lower prescribing — while appropriate for viral RTIs — may suggest 
disparities in care (24, 30, 45). One paper suggested that there may be differential rates 
of respiratory tract infection between races (35). However, this was empirically refuted 
in the definitive study on otitis media by Paradise et al. (48) and the approximately 700 
articles which cite it. Woods et al. also discussed the racial variation in prescribing for 
otitis media, and hypothesized several possible explanations: providers who worked 
predominately with minorities overall were more adherent to guidelines; providers were 
more adherent when treating minority children in particular; patient expectations led to 
overprescribing in non-minority populations; providers treating predominately minority 
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patients had differential exposure to pharmaceutical representatives compared to those 
treating majority patients; providers caring for minority patients tended to opt for 
cheaper visit resolutions; or structural racism (49). Testing each of these specific 
concepts in a single study would be exceedingly difficult as they likely overlap. An 
innovative methodological approach to evaluating the role of race in prescribing is 
needed to address conflicting results in the literature.  
Studying the interaction of provider and patient race may allow us to better 
understand how race affects prescribing. One study of racial variation in patients’ 
expectation for antibiotics concluded future research should investigate patient-provider 
racial concordance (27). Studies of race concordance – evaluating the effects when the 
patient and provider have matching races and when they do not – are rare in general and 
non-existent in studies of antibiotic prescribing for RTIs. In the literature that does 
exist, concordance was often interpreted as a way to include aspects of the patient-
provider relationship into analyses (50). An early, seminal article studying race and 
gender concordance evaluated how concordance affected how physicians involved their 
patients in treatment decisions (participatory decision making) (50). The authors found 
that when patients and physicians shared the same race, patients were more likely to 
score the visit as highly participatory, suggesting that racial concordance was capturing 
elements of cross-cultural communication. Better cross-cultural communication may 
make it easier for providers to explain why antibiotics are unnecessary for RTIs, and 
perhaps make it more likely that patients will understand and believe their provider. 
Poor cross-cultural communication may increase misunderstanding which could erode 
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the patient’s trust in the doctor or the health care system overall (51). Other research 
has also found racial variation in health literacy around antibiotics (52, 53), and 
effective communication is likely key to educating the patient. Given the important role 
of concordance found in other literature and the largely unexplained significant 
associations found between race and prescribing, future research should incorporate this 
important perspective into models of antibiotic prescribing for RTIs. 
 To properly examine the effect of race, future research needs to control for other 
important variables in the prescribing process. For example, previous literature has 
found that the age of the patient was associated with prescribing, with older adults (25, 
54, 55) and younger children (56–58) less likely to be prescribed an antibiotic, even 
though guidelines often do not differ based on age (59). Other demographic factors are 
also important including sex, where previous research has found men less likely to be 
prescribed (24, 25, 60, 61), and geography, where substantial variation has been 
documented (62–70), such as more frequent prescribing in the Southeastern United 
States (29, 46, 47, 71, 72). Geographic region may indicate cultural differences (73), 
socioeconomic determinants (74), health education (75, 76), or some other important 
source of antibiotic prescribing differences. Numerous studies have found that patients 
with more comorbidities are often more likely to be prescribed antibiotics for viral RTIs 
(38, 40, 77–81), while in children early exposure to any antibiotics has been linked to 
future development of comorbidities such as asthma or eczema (82, 83). To better 
address the threat of antibiotic overuse, researchers need to build predictive models that 
comprehensively and innovatively explain the prescribing process.  
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Repeat visits 
If a patient strongly demands an antibiotic from his or her provider, some 
doctors may yield to this pressure and prescribe, even when they are well aware of 
clinical guidelines to the contrary. Patient demand is cited by providers as a cause of 
antibiotic prescribing and has been verified in empirical research (84–90). For example, 
a study of nearly 3,500 adult patients concluded that those who expected antibiotics 
tended to get them (86), and interviews with U.S. providers found that while providers 
were aware of clinical guidelines, patient demand was the main barrier to responsible 
prescribing because they were worried about patient satisfaction with their care (91). 
The story is similar for pediatric patients. A study examining the relationship between 
parents, physicians, and antibiotics surveyed 610 pediatricians and found that 48% of 
the physicians reported that parents always, most of the time, or often pressured them to 
prescribe antibiotics, and 53% of them thought that parental demand was the single 
largest contributor to overprescribing in children (92). When patients seek antibiotics it 
can complicate the decision of the provider about whether or not to prescribe.  
An important consequence of antibiotic seeking may be an increase in repeat 
visits if an antibiotic is denied. One study of 17 million upper respiratory visits found 
that prescribing an antibiotic for a viral respiratory tract illness reduced the likelihood 
of the patient returning for a second visit for the same complaint (93). The increase in 
repeat visits among those not initially prescribed was small (2 percentage points). 
However, if antibiotic-seeking is rewarded, patients may expect antibiotics for RTIs, 
increasing future prescribing and visits for viral RTIs (94). Consequences associated 
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with unnecessary repeat visits include additional opportunities to be unnecessarily 
prescribed, increased medical costs, and inefficient use of medical resources (93). If 
denying a patient an antibiotic simply results in a dissatisfied patient and repeat visits – 
which occupies provider time – it may be difficult for the provider to focus on the long 
term harms of prescribing when prescribing an antibiotic provides the path of least 
resistance (94). Compared to the literature on overprescribing in general, very few 
studies have focused on how prescribing is associated with repeat visits for similar 
complaints, and more research could provide better insight on the issues faced by 
prescribers. 
Previous literature has demonstrated that provider behavior can affect antibiotic 
seeking behavior in patients. For example, providers may be able to educate receptive 
patients in order to reduce repeat visits. In general, educating the patient or parent can 
have a large effect on prescribing. For example, a survey at 36 day care centers in 
Massachusetts found that greater parent knowledge about RTIs was associated with a 
lower rate of antibiotic seeking in response to symptoms including clear rhinorrhea 
(odds ratio (OR) of 0.45), green rhinorrhea (OR=0.66), and cough (OR-0.57) (95). 
Large-scale interventions targeting patients have also shown some success (96, 97), and 
research consistently finds patients who are better educated about antibiotics and RTIs 
are less likely to receive an antibiotic when it is not necessary (98–100). This has 
important implications for populations with lower health literacy overall such as those 
of lower socioeconomic status (101) and non-white patients (101, 102), reinforcing the 
need for the effective cross-cultural communication outlined earlier in this chapter. This 
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education may be important for discouraging antibiotic-seeking, especially in pediatric 
patients, and may reduce antibiotic seeking over time. To that end, public educational 
interventions at the local (103, 104) and national levels (such as the CDCs “snort, 
sniffle, sneeze, no antibiotics, please” campaign (105)) may be an important tool to 
address gaps in health literacy. 
Provider attitudes 
Ultimately, only the provider has the ability to prescribe antibiotics, so it is important to 
understand the attitudes and beliefs of providers towards prescribing and how 
stewardship works to promote judicious use of antibiotics. Previous literature has 
suggested that prescribing attitudes can change over time in practice with multiple 
reports having found that providers more recently out of medical school – residents – 
prescribed more appropriately than more experienced physicians (106–108). However, 
many residents may be at risk for overprescribing. A survey of 182 residents across 11 
primary care programs found that while over 99% believed they had a good knowledge 
about treatment for upper RTIs, 57% of them also thought that antibiotics should be 
prescribed for acute bronchitis (109). In actual practice, however, residents have been 
shown to prescribe less frequently than more experienced physicians. A study using 
NAMCS and NHAMCS found that more experienced physicians prescribed antibiotics 
for 34% of visits for respiratory diagnoses where antibiotics are rarely indicated 
compared to 21% for residents (110). These findings suggest that while recent exposure 
to medical education may promote appropriate prescribing relative to other physicians, 
there is still room for improvement, such as through education and feedback 
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interventions (111).  
 Fellows, physicians who further specialize after completing a residency in 
internal medicine, are more advanced than residents, but still learning from more 
experienced attending physicians. The Infectious Diseases Society of America (IDSA), 
the professional society for infectious disease practitioners, describes the goal of ID 
fellowship to “provide training and supervised experience at a sufficient level for the ID 
fellow to acquire the competency of a specialist in the field of infectious diseases” 
(112). Fellows gain this experience through didactic learning, direct patient contact, and 
other educational experiences (112). ID fellowship programs routinely include 
opportunities for fellows to engage in antibiotic stewardship activities as the IDSA 
recommends that any antimicrobial stewardship team be led by an infectious disease 
physician (113). In this way, infectious disease fellowship programs are training the 
“stewards of tomorrow,” and, fellows are often specifically trained to promote 
antibiotic stewardship (114, 115).  
 A significant research gap exists regarding how ID fellows view their role in 
stewardship. This includes how they interact with other providers to encourage 
stewardship, the importance they place on stewardship, and whether they feel they have 
the tools necessary to promote stewardship beyond their fellowship. Because ID fellows 
play an instrumental role in promoting stewardship, their insights are useful for 
understanding how stewardship works on-the-ground and the effect this could have on 
intervention efforts. Key to improving stewardship is understanding the attitudes and 
beliefs of those who are responsible for promoting stewardship now and in the future.   
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Describing antimicrobial stewardship 
According to the Association for Professionals in Infection Control and 
Epidemiology, “antimicrobial stewardship is a coordinated program that promotes the 
appropriate use of antimicrobials (including antibiotics), improves patient outcomes, 
reduces microbial resistance, and decreases the spread of infections caused by 
multidrug-resistant organisms” (116). These coordinated programs can take on different 
forms depending on where they are implemented and the professionals involved in the 
implementation. In general, there are four broad strategies for implementing 
antimicrobial stewardship. These strategies include education and guidelines, formulary 
restrictions and preauthorization, audit (or “review”) and feedback, and computer 
assistance (115). Each strategy has unique characteristics that may be more or less 
effective depending on the setting, and it is possible to combine strategies for a broader 
approach to antibiotic management.  
Education and guidelines interventions involve creating prescribing guidelines 
for antibiotic use and then educating clinicians as to proper antimicrobial use (117). A 
study of one 600-bed hospital found that total antibiotic use fell 50% following the 
introduction of educational lectures on proper antibiotic prescribing (118). This type of 
intervention may also be effective in the initial decision regarding which antibiotic to 
use. The introduction of guidelines and educational programs in an emergency 
department in The Netherlands approximately doubled the number of sputum and urine 
cultures obtained (28% to 50% and 50% to 100%, respectively) which had the potential 
to improve resistance tracking and future stewardship efforts in emergency settings 
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(119). This approach was also validated in a randomized control trial setting. A cluster 
randomized controlled trial of 24 nursing homes in the US and Canada found that 
education decreased the inappropriate use of antimicrobials for urinary tract infections 
(120). However, education alone may not be enough to change outcomes. Analysis of 
data from 50 intensive care units at 20 US hospitals failed to find a significant change 
in rates of vancomycin (a powerful antibiotic often restricted) prescribing following 
dissemination of the national guidelines on vancomycin use (121). A possible 
alternative is to combine education with another strategy. Combining education with 
audit and feedback has been shown to be successful, as described by a randomized 
controlled trial in Pennsylvania and New Jersey which found that a one hour education 
session followed by a year of quarterly audit and feedback reduced broad-spectrum 
prescribing by 12.5 percentage points (122). In a study of 1,626 patients at a Canadian 
teaching hospital researchers paired education about appropriate antibiotics in the 
surgical setting with a formulary restriction reflecting that education, leading to an 
increase in appropriate prescriptions from 36% to 79% (123). A step-wise intervention 
beginning with education followed by formulary restrictions and then by prospective 
audit may also be an effective way to encourage judicious use of antibiotics. Following 
the implementation of this intervention in a 250-bed hospital in Argentina, a large 
decrease in prescribing resulted in cost savings of over $900,000 paired with a rise in 
the proportion of all prescriptions which were appropriate from 27% to 63% (124). 
Formulary restriction and preauthorization involve removing certain antibiotics 
from hospital formularies (formulary restriction) or requiring providers to obtain 
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approval before using certain powerful antibiotics (preauthorization) (113). The IDSA 
has found both strategies can be useful in immediately curbing the use of antibiotics 
(113). For example, a study of an intervention that restricted use of ceftazidime and 
ceftriaxone found use of those agents decreased by 95–97% and 86–95%, respectively 
(125). Moreover, there is evidence that this effect may be sustainable. In a study of over 
1,000 infants in the NICU restricting ceftazidime led to a 96.5% reduction in use which 
was sustained at six months (96.1% reduction) (126). However, this sustainability may 
differ based on site or patient population: a study of restricting cefuroxime for over 200 
elderly care units in the UK found that after one month of the intervention use was 
reduced by 75%, but by six months this reduction had fallen to 60% (127). Like 
educational interventions, it may be effective to combine these interventions with other 
strategies. At a major teaching hospital in Australia restricting use of cefotaxime and 
ceftriaxone as well as employing audit and feedback reduced the prescription of those 
drugs from 38 defined daily doses per 1,000 occupied beds to just under 16 (128).   
In audit and feedback strategies, select antimicrobials are reviewed to assess 
appropriateness and the results are reviewed with either individual providers or groups 
of staff (113). In the outpatient setting audit and feedback often takes place at a 
predetermined time interval (such as quarterly audits) and frequently presents aggregate 
data on prescribing performance (129). In the inpatient setting, audit and feedback is 
concerned with individual providers and patients, and often occurs in a more targeted 
fashion (129). These programs are time and labor intensive (as they require an 
additional professional to review prescribing decision, although this is often required 
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for preauthorization as well), but can have profound effects. A five-month audit and 
feedback program instituted in a hospital with 1,100 beds resulted in a 27% reduction in 
total antibiotic use – due to both fewer antibiotic initiations as well as shorter durations 
– without negatively affecting patient outcomes (130). However, the effectiveness of 
audit and feedback may be conditional on how regularly the review is conducted. A 
study of 55 ICUs where drug use was reviewed “periodically” failed to find a 
significant change in vancomycin use, even when combined with education (121). 
However, the lack of details about the audit and feedback intervention in the study 
suggests that it may not have been implemented across the sites with high fidelity, 
which could have biased the observed effect (131). For example, another study 
combining education with audit and feedback in Norway involved giving structured 
written and oral feedback to providers every three months, and over the course of the 4-
year combined intervention, antibiotic use was reduced by 50% (118). Audit and 
feedback can be a powerful tool to educate and train providers, but requires careful 
thought about implementation compared to a restriction-based strategy.  
Finally, computer assistance involves leveraging electronic health records and 
computerized provider order entry platforms to guide physicians to order the correct 
antibiotic with a series of prompts and other pop-ups (115). One vignette study found 
an 11.5 percentage point reduction in aggressive antibiotic treatment such as the use of 
broad-spectrum antibiotics depending on the way prescribing options were presented in 
the electronic health record (132). However, other researchers have also cautioned that 
over-reliance on computerized prompts can work against educating providers to the 
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disadvantages of overprescribing (133). In an effort to combat MRSA infection rates, a 
Veterans Affairs hospital used a computer pop-up to discourage providers from 
prescribing fluoroquinolones. As a result, fluoroquinolone use dropped 34%, however 
use of other antibiotics such as cephalosporins increased (134). It may be useful to 
combine computer assistance with other strategies. A major academic, urban medical 
center in Ohio found that implementing electronic order forms for uncomplicated 
urinary tract infections in the emergency department increased guideline adherence 
from 44% to 68%, and then rose further to 82% after adding the audit and feedback 
strategy (135).  
Conceptual framework 
 A conceptual model to understand what factors inform the prescribing decision 
is at the core of this dissertation. By combining the Cabana model (2) explaining 
physician noncompliance with clinical guidelines and Halbesleben’s organizational 
theory explaining provider behavior (136), I created a comprehensive conceptual model 
to understand how patient, provider, and practice factors interact in the prescribing 
process.  
The Halbesleben model defines work-arounds in the health care setting while 
differentiating them from related, but distinct, constructs (136). The authors defined the 
work-around from previous literature as "work patterns an individual or a group of 
individuals create to accomplish a crucial work goal within a system of dysfunctional 
work processes that prohibits the accomplishment of that goal or makes it difficult" 
(136, 137). The conceptual model of work-arounds is presented in Figure 1.1. The 
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authors examined the conditions leading to work-arounds, work-arounds themselves, 
and the consequences of work-arounds. Halbesleben et al. frame conditions leading to 
work-arounds as blocks to workflow. The authors identified several different types of 
blocks, which were characterized as institutional (protocols, administrative blocks) or 
individual (the people involved). For example, an institutional block may be an 
administrative form, which a provider believes is unnecessary and delays him or her 
from visiting with a patient. These blocks can be intentional or unintentional. In the 
above example, if the administrative form is a safety checklist meant to slow the 
provider down so he or she can think about the upcoming visit, the block is intentional, 
because it is meant to encourage thoughtful consideration and protect patient safety. On 
the other hand, if the purpose of the form is to bring the provider up to date on the 
patient’s conditions and 
speed up the visit, the block 
is unintentional because it 
was meant to promote 
efficiency but instead 
slowed the provider down. 
Table 1.1: Work arounds and related constructs 
Behavior Description  
Work-around Deliberate, non-malicious, response to 
some external stimuli in order to achieve a 
desired outcome 
Error A mistake leading to an unintended 
outcome 
Deviance  Deliberate action primarily for personal 
gain 
 
Conditions leading 
to work-arounds 
 
• Workflow blocks 
o Types 
o Intentionality  
Work-arounds 
 
 
• Definitions 
• Distinction from 
other constructs 
 
Consequences of 
work-arounds 
 
• Employee 
• Patient  
• System 
 
 
Figure 1.1: Halbesleben conceptual model of work around. Figure adapted from Halbesleben et 
al. (137). 
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Next, the authors defined the concept of the work-around by contrasting it with similar 
constructs (Table 1.1). Halbesleben first defined error, where the outcome is unintended 
and accidental. In work-arounds, an individual consciously chooses to violate the 
established work process in order to achieve some goal. Next, the construct of deviance 
is similar to work arounds in function – deliberately violating the established work 
process – but differ in motives. Deviances generally tend to be self-serving (136) 
whereas for work-arounds the motive is simply to complete a desired task. Finally, 
work-arounds produce consequences, which can either be positive or negative 
(136)(Figure 1.1). Employee satisfaction can be affected by work-arounds, either 
positively if the work-around makes the job easier or negatively if the work-around is 
seen as a hassle. Patients may be negatively affected if the work-around circumvents 
safety protocols and leads to an increase in medical errors. Finally, work-arounds can 
affect the system if one work-around leads to more work-arounds if employees see 
them as acceptable. Ascertaining these consequences is important to assess whether the 
change in workflow should be stopped or whether it is an effective solution to 
delivering positive results in the face of workflow blocks.  
Cabana et al. proposed that a collection of barriers stand between providers and 
guideline adherence (Figure 1.2). These barriers affect physician knowledge of, 
attitudes towards, and behavior in relation to guidelines (2). First, lack of awareness 
and lack of familiarity are barriers to a physician’s knowledge of a guideline. It is 
possible that a physician is simply unaware of the existence of a guideline, so cannot 
adhere to it. Even if a physician is casually aware of a guideline, they may not be 
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familiar enough with the recommendations to correctly apply the guidelines (2). Next, 
the authors outlined four barriers to positive attitudes towards the guideline: lack of 
agreement, where physicians who disagree with a guideline are less likely to follow it; 
lack of self-efficacy, where physicians believe they are unable to adhere to the 
guideline; lack of outcome expectancy, where physicians do not believe that the 
guideline will yield the desired outcome; and inertia of previous practice, where 
physicians may not have sufficient motivation to change ingrained practices. Finally, 
the authors note that “appropriate knowledge and attitudes are necessary but not 
sufficient for adherence” (2). External barriers can still challenge a physician’s ability 
to follow guidelines, including patient, environmental, guideline, and practice factors.  
The models described by Halbesleben and Cabana are useful stand-alone models 
to describe certain health services questions, but do not fully explain prescribing alone. 
Halbesleben’s model lacks details of what barriers prevent guideline adherence, and the 
Knowledge Attitudes Behavior 
Lack of familiarity 
with guidelines  
 
Lack of awareness 
of guidelines 
Lack of agreement 
 
Lack of self-efficacy 
 
Lack of outcome 
expectancy 
 
Practice inertia & lack 
of motivation  
 
External barriers 
 
-Patient factors 
 
-Guideline 
factors 
 
-Environmental 
factors 
Sequence of 
behavior change 
 
 
Barriers to 
guideline 
adherence 
Figure 1.2: Cabana model of barriers to physician adherence to practice guidelines. Figure 
adapted from (2). 
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Cabana model does not address the consequences of guideline non-adherence. To 
address those limitations, I created a combined model of the prescribing process. 
The conceptual model 
Incorporating elements of Cabana and Halbesleben’s theories of physician behavior 
yielded my conceptual model, presented in Figure 1.3. The model is organized as a 
prescribing sequence of three distinct domains: how the prescribing decision is framed 
by the provider (what influences how the provider thinks about prescribing in general); 
the actual prescribing decision (whether or not the provider prescribes an antibiotic at a 
visit), and; the consequences of the decision to prescribe or not to prescribe an 
antibiotic. This dissertation will use the conceptual model to examine stewardship and 
the consequences of overprescribing. These domains are described in detail below.  
 
  
Conditions framing the 
prescribing decision 
Knowledge Attitudes 
Prescribing 
decision 
Consequences 
of decision 
Behavior 
Lack of 
familiarity 
with 
prescribing 
guidelines 
 
Clinical 
uncertainty 
Lack of outcome 
expectancy 
 
Practice inertia & 
lack of 
motivation  
 
Disagreement 
with guidelines 
Patient 
characteristics 
 
Provider & 
environmental 
/practice 
factors 
Public Health 
 Overprescribed  
 
Administrative  
Feedback/ 
Resource use 
 
Peer 
 Practice norms 
 Training 
influence 
 
 
Prescribing 
sequence  
 
 
 
 
Behavior 
sequence 
 
 
 
 
 
Barriers  
Figure 1.3: Conceptual model 
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Conditions framing the prescribing decision: knowledge and attitudes 
 The conditions framing the prescribing decision are informed by the workflow 
blocks Halbesleben et al. characterize as either institutional or individual (136). In the 
context of prescribing, institutional blocks could include unclear guidelines or 
administrative policies that deliberately discourage judicious antibiotic use (136). 
However, this seems unlikely. While this may exist in some facilities, stewardship 
programs are established in part to make such guidelines clear and promote their 
implementation (113). Many of the barriers or blocks described by Cabana et al. are 
related to provider knowledge and attitudes, which would imply workflow blocks are 
individual rather than institutional (136). If blocks to workflow are individual, this may 
suggest that directly engaging with what providers know about stewardship and how 
they think about judicious antibiotic use can be important for promoting proper 
antibiotic use.  
 Regarding knowledge, if a provider is unaware of a particular guideline, or 
unaware of its applicability to a certain diagnosis, this is a barrier to appropriate care 
(Cabana defines this as “lack of familiarity” and “lack of awareness,” respectively (2)). 
Also important to the prescribing process is clinical uncertainty – a provider might be 
concerned that a patient with a nonspecific upper respiratory infection has an 
underlying bacterial infection. Both are important for framing how a provider thinks 
about prescribing. If a provider is cautious, he or she may be less comfortable trusting 
his or her own diagnosis of a viral RTI, resulting in a higher propensity to prescribe 
“just in case.” And if a provider has no knowledge of a certain guideline, they will not 
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be in a position to carefully contemplate the issue. 
Attitudes also contribute to how a provider thinks about stewardship and the 
prescribing process, and are influenced in part by knowledge. Perhaps a provider is 
aware of the guidelines regarding antibiotic prescribing and viral respiratory infections 
but disagrees with them. This disagreement would prompt the provider to work-around 
the guideline and prescribe anyway. Alternatively, the provider could broadly agree 
with the guidelines, but deem them unimportant (Cabana’s “lack of outcome 
expectancy”). This is especially relevant for antibiotic overprescribing where the 
primary consequence is bacterial resistance. If a provider does not expect this to be a 
major problem, or values it less than the potential possibility (however small) that he or 
she missed a bacterial diagnosis, then the provider will prescribe an antibiotic. Finally, 
pure inertia may play an important role in prescribing; providers who have been 
practicing the same way for many years see little impetus for change, particularly with 
a lack of immediately observed negative clinical outcomes accompanying their 
prescribing behavior. 
The prescribing decision 
 The actual prescribing decision – deciding to prescribe or not to prescribe an 
antibiotic – is the behavior of interest. It is here that Cabana et al. observe that while 
provider knowledge and attitudes drive behavior, external barriers such as patient and 
environmental factors are relevant as well (2). Patient factors can include explicit 
demand for an antibiotic, and environment can include a busy clinic with little time for 
each patient encounter. There may also be interactive effects between patient, provider, 
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and practice factors, such as cross-cultural communication (patient race or provider 
race may modify the effect on prescribing). In this dissertation I am narrowing my 
focus to how these factors influence the decision to prescribe when it is unnecessary – 
overprescribing.  
Consequences of the prescribing decision 
 My proposed model presented above extends the Cabana model by including the 
consequences of the prescribing decision. Each of the outlined consequences could 
apply to prescribing or not prescribing. For this dissertation I focus on overprescribing, 
the consequences of which are especially important when seeking to understand why 
overprescribing is so prevalent: if providers see no negative consequences of 
overprescribing when it is easier (either clinically or in terms of patient satisfaction), it 
may be more difficult to institute change. However, any consequences that the provider 
does observe – increasing resistance among patients’ bacterial infections or a patient 
who was correctly not prescribed returning for care – can directly lead back to 
knowledge and attitudes. I conceptualize the consequences of prescribing as related to 
public health if the patient was overprescribed, administrative if the provider faces 
feedback or performance critique based on prescribing habits, and peer if a provider’s 
standing among his or her peers is affected by his or her prescribing (Figure 1.3). If the 
consequences are negative, this implies overprescribing is harmful and effort should be 
made to end it. If, however, prescribing is seen as beneficial in achieving desirable 
outcomes at minimal cost, then the consequences may encourage providers to keep 
prescribing. While my literature review of unnecessary antibiotic prescribing has 
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demonstrated it is clearly harmful, providers engage in the practice in order to achieve 
some outcome they view as beneficial; more work is needed to understand what these 
desired outcomes are and how best to combat overprescribing.  
Summary and dissertation aims 
Significance of the research 
The introduction of antibiotics fundamentally changed the battle against 
infectious disease, shifting from a paradigm where treatment was limited in availability 
and effectiveness to ready access to life-saving drugs. However, antimicrobial 
resistance threatens medical advances in this area, creating untreatable and fast-
spreading “super bugs” (8). Literature has demonstrated that resistance to antibiotics is 
associated with worse health outcomes, longer hospital stays, and higher mortality 
(138). This dissertation will inform the urgent public health efforts that are needed to 
better understand stewardship and prescribing in order to slow the emergence of 
resistance. 
Unnecessary use of antibiotics is the driving force behind the increase in 
bacterial resistance (139), but while surveys of physicians have found that they 
understand the threat of resistance, they are opposed to any restrictions on their own 
practice (140). However, despite the familiarity with guidelines over 50% of antibiotics 
given to patients with an upper RTI are inappropriate (60, 141). Findings from the 
literature suggest that effective and sustainable improvements in prescribing are not 
possible without a comprehensive understanding of the driving forces behind 
prescribing behavior.  
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A lack of understanding about the attitudes and beliefs of prescribers may 
contribute to the ineffectiveness of many stewardship interventions that do not 
incorporate suggestions from those working in the environment. One method to better 
understand antibiotic prescribing and stewardship as well as the challenges to good 
prescribing practices is to directly engage with prescribers through qualitative 
interviews (60, 142). Previous qualitative research generated several hypotheses to 
explain physician noncompliance with prescribing guidelines, including that providers 
were likely to follow the lead of their peers (143), providers did not see many of the 
negative consequences in their patients’ (144), and that, within the field, the immediate 
risks of missing an unlikely diagnosis outweighed any risk from overprescribing (145). 
But there are no studies exploring the attitudes and beliefs of providers at the frontline 
of stewardship efforts, infectious disease fellows (113). These providers may have 
unique insights into how stewardship works and can be improved as they are among the 
most involved with day-to-day stewardship.  
The threat posed by overprescribing has led to intervention efforts by the federal 
government (141) as well as state and academic establishments (146) – so far to limited 
effect (147). Many major interventions to date have focused on large-scale educational 
campaigns to inform providers and patients of current clinical guidelines, and 
interventions combining multiple approaches are less common. To reverse this trend, 
more research is needed to approach stewardship and overprescribing with innovative 
methods and measures. The conceptual model supporting this dissertation 
contextualizes the research by acknowledging that genuine lack of knowledge is often 
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not at the root of overprescribing and, indeed, focusing exclusively on education of 
providers misses the barriers and behaviors that are part of prescribing. In three distinct 
papers I explore new perspectives – including testing the effect of race concordance on 
prescribing, interviewing infectious disease fellows, and evaluating the effect of 
prescribing behavior – to better understand the prescribing process and to inform new 
interventions to more effectively promote the judicious use of antibiotics. Without 
thoughtful and innovative empirical investigation, future stewardship interventions are 
not likely to improve.  
Dissertation structure 
The unifying motivation of this dissertation is to explore, in a novel way, 
stewardship and overprescribing for RTIs, answering the question: What patient, 
provider, or practice factors promote judicious use of antimicrobial agents and 
how can insights from future stewards increase our understanding of the current 
state of antibiotic stewardship? Below I describe the goal of each paper: 
Paper 1. Examine the knowledge and attitudes of current ID fellows towards stewardship 
to understand how they perceive their role as antibiotic stewards;  
Paper 2. Determine patient, provider, and practice characteristics associated with 
unnecessary prescribing at the time of the visit including the role of patient-
provider race and sex concordance; and 
Paper 3. Assess the long-term consequences of overprescribing by studying how a 
provider’s decision to prescribe antibiotics at a child’s first encounter for acute 
bronchitis affects the likelihood of a future encounter and prescription.  
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Together, these studies will test how my conceptual model adds to the understanding of 
the complex prescribing process, specifically related to the phenomenon of 
overprescribing, and how stewardship functions in a real world setting. This dissertation 
will touch on each distinct point in the prescribing sequence from the attitudes and beliefs 
of providers around stewardship, to the determinants of overprescribing at the time of a 
visit, and how prescribing can affect future visits and prescribing. Following the three 
papers, I will conclude with a discussion of what my findings mean for future 
interventions and how the research community can continue to explore solutions to the 
current crisis of bacterial resistance due to unnecessary antibiotic prescribing. 
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CHAPTER TWO: A QUALITATIVE STUDY OF THE KNOWLEDGE AND 
ATTITUDES OF INFECTIOUS DISEASE FELLOWS – REAL WORLD 
EXPERIENCES OF ANTIMICROBIAL STEWARDSHIP 
Summary 
A key component of promoting stewardship is to understand the knowledge, attitudes, 
and beliefs of the stewards of the future: fellows working with and around antimicrobial 
stewardship. Specifically, this chapter will use qualitative research methods to examine 
the knowledge and attitudes of current ID fellows towards stewardship to understand how 
they perceive their role as antibiotic stewards. Findings from this chapter will describe 
how antibiotic stewardship functions “on the ground” and how fellows see their role as 
stewards as well as informing a framework for effective ways to promote antibiotic 
stewardship.  
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Figure 2.1: Conceptual domains of Chapter 2 
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The conceptual domain addressed in this study is bolded in Figure 2.1. I use this 
qualitative study to more thoroughly explore stewardship by soliciting the perspectives of 
current ID fellows. Through their perspectives I explored how stewardship is taught to 
and learned by fellows, and how that education is spread to other medical services to 
impact the prescribing process. The fellows discussed the benefit of proper stewardship 
and any barriers to stewardship such as organizational inertia that they experienced.  
Research question 
The goal of this chapter is to examine the knowledge and attitudes of current ID fellows 
towards stewardship to understand how they perceive their role as antibiotic stewards. 
Background 
There is a substantial body of quantitative literature describing the unnecessary use of 
antibiotics and the factors associated with that misuse (147). However, antibiotic use for 
RTIs remains stubbornly high (24, 25). Interventions designed to address overprescribing 
often fail for reasons we do not fully understand. For example, one group used 
information from previous studies to create an intervention involving persuasive 
communication to improve antibiotic management of uncomplicated upper RTIs, but this 
intervention did not alter the intention of the providers to prescribe antibiotics (148). 
However, like other literature documenting failed interventions, there was no in-depth 
communication with those providing the persuasive communication either before or after 
the intervention. That information could have provided insight into why the intervention 
did not work and inform future, more effective interventions. Indeed, compared to 
quantitative studies, qualitative explorations of antibiotic prescribing are rare. Yet a 
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systematic review of qualitative studies of antibiotic prescribing concluded that 
antibiotic prescribing was a “complex process” involving multiple factors and 
suggested that further qualitative exploration is necessary and would be beneficial (6). 
One benefit of qualitative research is better understanding the attitudes and beliefs 
behind the actions of physicians and their effect of the practice environment to inform 
future interventions. Interventions that are unsuccessful at changing behavior may be 
improved by asking providers directly their opinions of stewardship and the largest 
barriers to proper prescribing. By exploring the context and challenges faced by those 
tasked with supporting an intervention, qualitative techniques can inform future 
interventions that better reflect the realities in the work environment.  
 In a large medical center, the responsibility of promoting proper antibiotic use 
often rests with the Department of Infectious Diseases, and specifically the ID fellows. 
However, there are no published qualitative studies of ID fellows’ perspectives on 
stewardship, even though these fellows may have the best insight into how antibiotic 
stewardship is promoted at the facility and what hampers proper use. Instead, existing 
qualitative studies focus on the non-ID providers who are targeted by antibiotic 
stewardship programs (6). By soliciting insight from ID fellows I can better understand 
the role of stewardship in the hospital, how stewardship is communicated to other 
medical services, the challenges faced by fellows shouldering the burden of promoting 
judicious antibiotic use, and what role their commitment to the importance of 
stewardship might play in their future practice. 
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Methods 
Instrument development 
Review of the literature as well as prior work on the subject (24) informed the 
creation of a semi-structured qualitative interview guide (Appendix A). The guide 
included questions and probes related to the primary research question seeking to 
understand the knowledge and attitudes of future stewards and explore the aspects of the 
fellowship that best promote stewardship. Questions addressed the responsibilities and 
day-to-day routines of the fellows, their interactions with other providers, and general 
thoughts on antibiotic stewardship, their future careers, and potential improvements in 
their own fellowship program around antibiotic stewardship. I created the interview guide 
with input from the research team and pilot-tested the guide with an ID fellow at a safety-
net hospital. Following pilot-testing, the guide was updated to include new questions 
generated from the pilot interview, the structure was re-organized for better flow, and 
several questions were rewritten to improve clarity. The Boston University Medical 
Center Institutional Review Board approved the research. 
 Recruitment 
Fellows were recruited through email. The director of the ID fellowship at a large 
urban teaching hospital sent information regarding the study to other fellowship program 
directors across the country and asked them to forward the information to their respective 
fellows (see Appendix A). Any interested fellows were directed to email the study 
interviewer. The only criteria for inclusion were that the individual was a current ID 
fellow and another fellow from the same state had not already been interviewed.  
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My goal was to interview the fellows to gain a deeper understanding of their 
experience. I used iterative sampling, soliciting an interview from a different fellow from 
a different state until I reached saturation, where no new information or themes emerged 
from the data, which occurred after 17 interviews.  
Data collection 
 Fellows who agreed to participate scheduled a time at their convenience for a 30-
minute audio recorded telephone interview. The interviews took place between December 
2014 and June 2015. Fellows were assured that their participation would be kept 
confidential and were given a description of the study prior to the interview. To protect 
fellow confidentiality the IRB granted a waiver of documentation of consent and gave 
permission to obtain verbal consent only so that no identifying information was solicited 
during the recording. Interviews lasted an average of 37 minutes, with a range from 28 to 
50 minutes. Each fellow was compensated with a $50 gift card for his or her time. 
Data analysis 
Interviews were transcribed verbatim and after each interview was transcribed, 
the recording was reviewed again and the transcription checked for accuracy. Grounded 
theory was used to analyze the data (149). This method included an inductive analysis of 
the transcripts to extract theory from the data through a systematic analysis of each 
interview (150). To generate themes from the data, two members of the study team first 
independently reviewed the initial two transcripts to identify emergent concepts. The 
transcripts were reviewed line-by-line to describe important quotations and passages by 
conceptually grouping them. I developed codes from these concepts, coded the initial two 
		
33 
transcripts, and then met with a member of the study team to explore how well each 
concept categorized information, to add new codes where needed, and to revise the 
definition of each code as necessary. Through this process of refining existing categories, 
the resulting codes better reflected the data and I obtained consensus for the coding 
scheme. This yielded a comprehensive codebook containing all codes and definitions that 
could be used to code future transcripts. Using this codebook I coded the subsequent 15 
transcripts independently.  
Results 
Fellow characteristics 
I interviewed a total of 17 ID fellows from 17 states across the U.S. between December 
2014 and June of 2015 (Appendix A). The 
characteristics of the final study sample are 
described in Table 2.1. My sample included 
twelve men and five women. The majority 
identified as white, two identified as Hispanic, 
and four fellows identified as Asian. The range 
of time in fellowship was between one and three 
years, and most interviewees were in their 
second or third year of fellowship.  
Summary of findings 
The results of the analysis are presented in four distinct thematic categories that work to 
further our understanding about the attitudes and beliefs of ID fellows and how 
Table 2.1 Characteristics of Infectious 
Disease Fellows 
Gender n % 
Male 12 71% 
Female 5 29% 
Race/Ethnicity   
White 11 65% 
Hispanic  2 12% 
Asian 4 24% 
Region   
Northeast 4 24% 
Midwest 4 24% 
South 5 29% 
West 4 24% 
Year in Fellowship  
1 4 24% 
2 11 65% 
3 2 12% 
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stewardship works: (1) how antibiotic stewardship is taught and learned in the fellowship, 
(2) the role of the fellow in promoting stewardship, (3) how their stewardship role 
involves interactions with other providers and pharmacists, and (4) fellows’ suggestions 
as to what would improve the fellowship program antibiotic stewardship training.  
How antibiotic stewardship is taught and learned in the fellowship 
For all fellows interviewed, there was a distinction between actual clinical 
experience and fellowship tasks versus didactic learning through classes or seminars. By 
and large fellows referred to this distinction as “informal” versus “formal” education. 
Examples of formal didactic education include morning conference, a short “crash 
course” before the start of fellowship, or a national antibiotic conference. Informal 
education encompassed daily clinical responsibilities such as consulting with other 
providers or dispensing prescribing advice. All fellows also agreed that informal 
education was by far the most dominant form of education because, as one fellow put it, 
“I feel like antimicrobial stewardship itself is kind of a part of what we do on a daily 
basis.” One fellow summed up the importance of informal education: 
“We have random lectures about stewardship […] but given the volume I think 
given the amount of work we have especially the antibiotic approvals of course in 
the process when you’re doing ID consults I mean it’s part of it so it’s sort of a 
given you’ll just learn it while you’re working.” 
And another fellow noted that while “we get some training as far as didactics during our 
fellowship”, “most of that quickly becomes “how do we, along with our attending 
physicians, commonly use this antibiotic in clinical practice.”  
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Didactics were seen as most valuable at the very beginning of the fellowship 
experience in order to lay the “groundwork” for later clinical experience. One fellow 
thought that early didactics were “absolutely essential” in order to be in the position to 
“ask clinical questions about the finer points of which drug you're using.” Another 
echoed this sentiment emphasizing the importance of didactics in conveying a baseline of 
knowledge, a “general awareness” not just for ID fellows, but for other medical providers 
in the hospital. Only one fellow thought the entire enterprise of antibiotic stewardship 
education was fruitless, remarking “I don't think education works very well, 
unfortunately. I wish it did. I mean I think I think at the end of the day what you need is 
top-down heavy-handed control.” This fellow may have been referring not to his own 
education but rather the value of educating other clinicians, which he may be interpreting 
as less effective than simply taking charge with formulary restrictions or other top-down 
control mechanisms.  
The role of the fellow in promoting stewardship 
 Fellows defined their role in two main ways. First, fellows described how 
stewardship fit into fellowship and stewardship shaped their role as fellows. While many 
fellows stated that antibiotic stewardship flowed through most of what they did, this 
expressed itself in different ways, including in interactions with other providers and 
independent research. Second, fellows described how their stewardship role was often a 
burdensome aspect of the fellowship, especially when they were required to carry an 
antibiotic pager for long periods of time.  
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Stewardship in the fellowship 
 When beginning fellowship, fellows were faced with two primary roles: (1) 
responding to antibiotic pages and (2) serving as consults for other medical services. The 
emphasis on these roles varied between programs as well as across years of fellowship.  
 All fellows worked at a hospital that used restriction as a form of antibiotic 
stewardship, some with a single restricted antibiotic and some with so many fellows need 
to carry around a list of them all. In some cases, restricted antibiotics were approved by 
the pharmacy, but in the majority of programs fellows were the gatekeepers of restricted 
antibiotics and carried a special antibiotic approval pager to handle these requests. This 
responsibility rotated among fellows, and first-year fellows tended to cover the pager 
more often than second- or third-year fellows. 
 Consulting for other medical services on the use of antibiotics or other ID topics 
was the primary clinical work of the fellows. These experiences ranged from highly 
cerebral, where fellows were able to solve a mystery to correctly diagnose a disease or 
propose an effective treatment course, to exercises in antibiotic approval from physicians 
who already knew what they wanted and expected the fellow to approve the request 
without much independent thought. Most consults were in between these scenarios, and 
several fellows gave similar examples of consults that focused on de-escalation of 
antibiotics (switching from a broad- to a narrow-spectrum antibiotic for example) or 
suggesting the proper approach for deciding on antibiotic treatments e.g., for urinary tract 
infections or methicillin-resistant Staphylococcus aureus. Another common consult had 
to do with asymptomatic bacteriuria, explained by a second-year fellow in the Northeast: 
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“The point is that in ID we recognize […] treating what we call asymptomatic 
bacteriuria, a patient who has some bacteria in their urine but has no symptoms, 
there's a lot of literature that says you don't need to treat that, that's not an 
infection, and giving them an antibiotic you know doesn't help them at all is a 
situation where they're treating something that wasn't really an infection, they 
gave an antibiotic that clearly caused harm and they want to know what else to 
give them and I said just don't give them anything you don't, you have no 
infection to treat here.” 
The fellow was illustrating a case where doctors had treated asymptomatic bacteriuria 
with trimethoprim/ sulfamethoxazole, which can have the adverse effect of contributing 
to renal failure, which it did in his illustration. The fellow concluded with the observation 
that sometimes his role is simply to “provide reassurance …in not treating something that 
they think may be an infection but actually isn't.” 
Burden of stewardship in fellowship  
The major burden of stewardship was the antibiotic pager. Oftentimes, among 
those who had to carry such a pager, fellows were required to respond to pages at all 
hours of the night. At the facility with a single restricted antibiotic, it was rare to get a 
night time page as the hospital “luckily [didn’t have] that many cases that were put on 
linezolid overnight.” Conversely, a first-year fellow currently covering the pager was 
frustrated with the number of overnight pages:  
“[I]t’s really common that most of the pages I get overnight are antibiotics [...] 
Here we actually have to approve it overnight which is I think not the greatest 
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thing just because at three o'clock in the morning when I'm getting awakened for 
the 4th time that night I'm probably not providing adequate medical care.” 
A different first-year fellow who reported receiving between eight and ten pages for 
restricted antibiotics a day expressed concern that such frequent pages may conflict with 
other medical care, noting that it “interferes […] when you have a lot [of] consults and 
patients to see and you’re the only one doing it.” Among fellows who did not have 
dedicated antibiotic pagers, pharmacists tended to be the first line of approval or there 
were certain antibiotics that physicians could begin administering to a patient as long as 
they requested a formal ID consult soon after. One fellow explained the rationale of his 
program for not requiring fellows to carry antibiotic pagers: 
“[The program doesn’t] really believe that there's a lot of true education in 
[having fellows carry the antibiotic pager] and first-year fellows probably don't 
necessarily have the knowledge to make those decisions either, it really is an 
attending-level decision on whether you're like giving an antibiotic or not. And 
particularly when they're talking about those antibiotics that we're trying to quote-
unquote protect.” 
One fellow also noted that while pharmacists were the gatekeepers for restricted 
antibiotics during normal operating hours, fellows were invited to cover the antibiotic 
pager as an elective for those interested in stewardship. In her program, however, fellows 
already covered the antibiotic pager after hours, and several of her day-to-day consults 
were little more than requests for restricted antibiotics. 
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Interacting with other providers and pharmacists in a stewardship role 
 Interacting with others was a major part of how fellows promoted stewardship. 
Two types of interactions were identified: where fellows consulted with other services 
and encouraged stewardship directly and when fellows interacted with pharmacists and 
received assistance to better promote stewardship. When interacting with other services 
fellows either consulted in depth to select the correct antibiotic treatment or responded to 
antibiotic approval requests and described the successes and challenged they faced in 
both.  
Consulting with other services and antibiotic approvals 
One of the most important responsibilities of the fellow is to serve as a consult for 
other medical services. Frequently, these consults involve selecting the correct antibiotic 
– type, dosing, and length of therapy. Fellows described two overarching types of 
interactions: formal consults which often entailed earnest solicitation of advice from the 
fellow and antibiotic approval requests where the fellow was approached with a 
preconceived idea of the appropriate treatment course.  
 When agents are restricted and providers are required to go through ID fellows as 
gatekeepers tensions can grow. One fellow expressed his frustration, remarking “of the 
opinions that are ignored, ID typically rates number one.” Sometimes this is because 
residents in other services are requesting antibiotic approvals on behalf of an attending 
physician who has given them specific orders for antibiotics, and other times simple 
physical exhaustion is a culprit as one fellow explained “when I have to approve agents at 
night, you're not going to make any friends if you're going to be a really strict draconian.” 
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These exchanges, though, can also be a form of education, forcing fellows to be able to 
explain antibiotic restrictions: 
“sometimes [other medical services] get really angry at you when you won’t give 
them a certain antibiotic at two in the morning, this happens a lot, and you just 
kind of like get used to communicating your knowledge to them. I think that 
prepares you for working with people later on. Some people are really mean. It 
does kind of test your deeper understanding of things. Like when somebody’s 
really pushing you for something because they just don’t understand […] [It] 
really makes you have to know what you’re talking about.” 
At the end of the day, at many hospitals the treating physician can override antibiotic 
restrictions if he or she deems it medically necessary. When this occurred, fellows most 
often mentioned surgeons as the stubborn prescribers: 
“especially surgeons, we have a little harder time with them. […] they say ‘well 
we'll see what we can do.’ […] If they're not going to respond it's most likely to 
be a surgeon or an urologist.” 
However, even fellows who described tensions with other services were quick to point 
out that most interactions were positive, and that all providers were acting in the way they 
felt was best for the patient. In general, many services who called for consultations were 
genuinely seeking advice from an ID expert and, as one fellow put it, were “happy for the 
helping hands.” One fellow described how she learned to approach other services in a 
“nice way” during her fellowship and discovered that many other providers appreciated it 
when she provided them with a rationale for different antibiotic treatment strategies. This 
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education by the fellow was a way to foster engagement and buy-in from the other 
providers, leaving them “very receptive and happy.”  
The importance of pharmacists 
Clinical pharmacists are also important antibiotic stewards in the hospital. 
Programs that did not have a fellow carry around an antibiotic pager for release of 
restricted antibiotics often used pharmacists for this role; pharmacists in some programs 
took over stewardship roles overnight if the fellows were not on call, although this was 
rare. One antimicrobial stewardship program was started and wholly run by pharmacists. 
Beyond administering stewardship programs, the pharmacists were very involved in 
assisting the fellows in stewardship responsibilities. When asked if he felt prepared for 
the stewardship responsibilities he faced during his first year of fellowship, one fellow 
responded: 
“Oh no, that's why we had our trusty pharmacist. I owe her a lot of what I know 
now, she would tell me 'yea you gotta call them and ask them this way' and I 
developed my own way of telling them but I wasn't prepared before and she 
would say 'yea this medication is not indicated for this' and I've been learning 
from her a lot so without her it would be really, really, really tough. So yea, we 
will always have the pharmacist.” 
While only this fellow used the moniker “trusty,” the sentiment of the pharmacist as a 
knowledgeable source that could help fellows answer complex questions around 
antibiotic choice, dosing, and duration was widespread. One fellow named the ID 
pharmacists the aspect he “liked most about [the] training program” regarding antibiotic 
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stewardship because of the insight he gained when rounding with the pharmacists as well 
as the ability to call a pharmacist with any sort of drug related question. In many 
hospitals the pharmacists also tracked antimicrobial resistance, and this was useful 
information for the fellows when they needed information concerning a patient. One 
fellow gave an example when pharmacist review of labs was useful for successful 
stewardship with other medical services: some surgical teams bristled at the notion of an 
ID doctor noticing an odd blood culture and suggesting proper antibiotics (“why is [he] 
reviewing [my] patients?”) while this was seen as a routine and non-threatening when 
done by a pharmacist.  
Improving the antibiotic stewardship in the fellowship program 
Soliciting feedback on what fellows believe can be improved about antibiotic 
stewardship in the fellowship program provides useful insight. Overall, fellows were very 
happy to open up about the potential improvements for their fellowship program. In fact, 
one fellow gave that as his prime motivation for participating in the interview: 
“I've seen the potential problems associated with [antimicrobial stewardship] so I 
think one thing was just talking with somebody about the issues and kind of 
providing that feedback. This is the first time as an ID fellow that my opinion has 
been asked for in a study [laugh].” 
This characterization of antimicrobial stewardship programs not asking for feedback was 
rebutted by one other fellow who commented that he felt like the program was asking 
about ways to improve the program “all of the time,” but either way fellows were not 
hesitant to share their thoughts about deficits in their programs. Several fellows expressed 
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that while there was nothing explicit they would change in their program, they believed 
sharing their experiences could add to the discussion around the best way to conduct 
stewardship. For those with direct suggestions, two main concerns were cited: restriction 
policies and stewardship education.  
Updating restriction policies  
For those who had to carry an antibiotic approval pager, this pager was the 
primary source of burden in their daily routine and also the aspect they wanted to see 
changed. One fellow explained his main suggestion was to have a dedicated pharmacy 
team to deal with the antibiotic restriction program rather than relegating that to fellows. 
One fellow had a specific suggestion for the overnight pager: 
“Have a pharmacist somebody who is actually working in the hospital overnight 
carry the pager say 7pm until 7am or some time like that. I think that would … for 
the fellows I think it would help us be at our best while we're actually performing 
consults on a daily basis.” 
This fellow stated that generic clinical consults were the main, more important, task and 
overnight pages were so disruptive that the fellow was not able to perform as well the 
next day. In general, fellows agreed that pharmacists were qualified to decide whether or 
not an antibiotic could be approved and that carrying the pager was both non-educational 
and could potentially result in less appropriate care. Fellows did not mind doing tedious 
work, but tedious work that failed to provide either education or better clinical care was 
often viewed as counterproductive to the goals of antibiotic stewardship. 
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Improving education  
Fellows recognized the benefit of formal stewardship education, but felt that their 
programs often were not committed enough to the educational aspects of the fellowship. 
For education, fellows felt that the other services in the hospital could benefit from 
structured stewardship lectures as well, with one fellow suggesting that the hospital: 
“[R]equire more of those direct interfaces with the stewardship committee in the 
hospital, and maybe it’s on a quarterly basis or a semi-annual basis because they 
are certainly informative and you, you see how those discussions are happening 
and what the areas of focus are for the hospital committees.” 
This interface with the hospital stewardship committee was suggested as beneficial not 
only to the fellow, but to the entire hospital community as well. Other fellows 
commented on the potential benefit of educating all providers about the benefits of 
stewardship to not only improve good antibiotic use but also to improve communication 
and understanding between ID and other medical services. Additionally, very few fellows 
knew how antibiotics were selected to be restricted. Often they knew of the committee 
that decided such things, but were unaware of the inner workings.  
Discussion 
This study responds to recent calls in the literature for qualitative research in order to 
better understand antibiotic stewardship (6) and adds to knowledge about how 
stewardship works in a fellowship program. Fellows described the challenges they faced 
when practicing stewardship. Their descriptions provided a context for failed stewardship 
interventions documented in the literature which rarely follow-up with staff to explore 
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why the intervention was unsuccessful (148). Additionally, my results are useful for 
framing how fellows view stewardship for program directors. When asked about 
stewardship overall, fellows frequently interpreted stewardship to mean antibiotic 
restriction programs and responding to requests for antibiotics. Stewardship encompasses 
much more, and strategies to promoted judicious use of antibiotics include more than 
restrictions. The fact that fellows view stewardship in this way is an important message 
for fellowship program directors designing stewardship curricula.   
In the interviews, fellows described the methods, related to both education and 
practice, they believed to be most helpful in promoting stewardship and aspects of 
fellowship that should be improved. This insight could be helpful for understanding how 
an intervention might fit into the day-to-day stewardship experience. For example, 
fellows addressed potential challenges to promoting the judicious use of antibiotics, 
describing tension with other providers who did not agree with stewardship guidelines 
and suggesting that some stewardship policies, such as requiring fellows to carry a pager 
overnight, may be so burdensome as to be counterproductive. The attitudes of the fellows 
about working with other specialties contribute to the understanding of how the 
interaction between other providers and ID fellows influences the stewardship mission. 
The perspective of the ID fellow has never been directly explored in this way, and 
provides greater understanding for how stewardship is promoted among non-ID providers 
(115).  
 This study has several limitations. I interviewed ID fellows, so any inferences are 
restricted to that sample. As with any qualitative study, the results are not meant to be 
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generalizable; instead they represent an in-depth exploration of the attitudes and beliefs 
of my study sample. While not generalizable, this in-depth analysis is useful for 
designing interventions or exploring different methods to implement stewardship 
programs, as this level of detail is not available in quantitative research.  
Based on these results, I have four recommendations. First, fellowship programs 
may benefit by leveraging the aspects of the program fellows found the most valuable – 
complex problem-solving and working with other physicians to provide the best possible 
clinical care and promote antibiotic stewardship. Fellows embraced the role of 
stewardship and saw the responsibility of choosing the right drug, dosing, and duration as 
a part of the larger clinical puzzle, and enjoyed it. Dedicating more time to these sorts of 
tasks may encourage inter-specialty communication around stewardship. If less popular 
tasks such as antibiotic approval were framed as problem-solving puzzles, perhaps by 
encouraging dialogue during approval requests and emphasizing the importance of 
routine approvals to the overall goal of stewardship, fellows might see these activities as 
less burdensome and more effective for promoting stewardship. 
Next, fellows may also be receptive to more formal educational settings, and this 
might help them communicate better with other providers during consults to better teach 
stewardship to other providers. This could mean increased cross-service seminars, or 
interactive classes emphasizing the importance and practice of stewardship. Education 
could affect more than just the fellows themselves – a good environment that promotes 
stewardship may address some of the interpersonal conflicts faced by fellows.  
Additionally, programs may want to re-frame aspects fellows thought were most 
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frustrating and least useful. Fellows do not mind any task inherently, but bristle at things 
they view to be non-educational and unhelpful to the patient, such as answering antibiotic 
pages in the middle of the night. At a busy hospital where time is limited, fellows are 
forced to pick their battles, as one put it, and this hampers their ability to promote good 
stewardship. Sometimes conflict over antibiotic approvals with other services and 
tediousness made fellows wonder if what they were doing was “worth it” and it is likely 
important to emphasize those things such as positive collaboration and medical problem 
solving that yield vivid examples of the importance of stewardship. Part of fellowship 
may be to teach fellows that certain stewardship tasks, which feel tedious and unhelpful, 
are actually necessary. Fellowship programs may be able to communicate the message 
more effectively by emphasizing how these tasks benefit patient care or re-frame tedious 
tasks as problem solving activities to encourage active engagement on the part of the 
fellow. 
Finally, programs may want to encourage fellow engagement in how the 
stewardship program is run. In my interviews, fellows wanted to provide their 
suggestions for a better program, and by and large enjoyed working with others to 
promote stewardship. Using these desires in a creative way might promote better 
stewardship education throughout a health care institution. For example, working with 
fellows to implement improvements to the program could encourage more active 
engagement with the institution and promotion of stewardship if fellows are invested in 
the success of their proposed changes. If there are specialties which are struggling to 
meet stewardship goals, such as reducing overprescribing, fellows could act as 
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ambassadors to these other providers to explain how their day-to-day responsibilities 
promote stewardship. If fellows want to take on responsibilities aimed at improving 
stewardship, encouraging them to work with other specialties – such as in special 
interactive seminars, or more cross-specialty rounding – could promote stewardship 
throughout the institution. 
This study has explored the successes and challenges faced by ID fellows and my 
findings contribute to a more comprehensive understanding of the attitudes and beliefs of 
ID fellows. Future studies should aim to collect a diversity of options and specifically ask 
participants about the recommendations I have presented here to ascertain how relevant 
and realistic they are. The insights from this study can inform future research and 
interventions to better ensure more judicious use of antibiotics and improve clinical care. 
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CHAPTER THREE: PATIENT-PROVIDER RACE AND SEX CONCORDANCE 
IN PRESCRIBING 
Summary 
Overprescribing is by far the most common form of inappropriate prescribing which 
leads to increased antimicrobial resistance and can increase morbidity and mortality in 
some patients. To model overprescribing, I conducted a retrospective analysis in a large 
urban hospital of prescribing rates for those diagnosed with acute bronchitis, a viral 
infection that does not require antibiotic treatment in healthy children and adults. 
Incorporating variables that describe provider background and practice, patient 
demographics, and relevant clinical attributes can identify mechanisms influencing 
prescribing behavior.  
 Figure 3.1 displays the domains of my conceptual model that this chapter 
addresses. The primary focus is the behavior of prescribing – i.e. which factors influence 
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Figure 3.1: Conceptual domains of Chapter 3 
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an inappropriate outcome. In this quantitative study I analyzed which patient, provider, or 
practice factors are associated with overprescribing.  
Research question 
The goal of this chapter is to determine the patient, provider, and practice characteristics 
associated with unnecessary prescribing for acute bronchitis at the time of visit including 
the role of patient-provider race and sex concordance. 
Background 
Antibiotics are prescribed for acute bronchitis over 50% of the time despite clinical 
guidelines strongly advocating against the practice (138). Efforts to combat 
overprescribing in outpatient settings have proven largely unsuccessful (151). This lack 
of success is worrisome given increasing bacterial resistance; the CDC estimates that 
over two million individuals were infected with antibiotic-resistant bacteria in 2013 
(138). Better characterizing the prescribing decision may inform the development of 
more effective antibiotic stewardship interventions. Previous research has demonstrated 
associations between overprescribing and patient factors including age, sex, and 
comorbidities (24, 54); physician factors such as years in practice, teaching experience, 
patient volume, and specialty (24, 38); and variation in geographic region (24).  
The patient-provider relationship is likely very important. Patient expectations, 
the provider’s perception of a patient’s preferences, and communication have been 
suggested predictors of antibiotic overuse. Race and sex may impact the patient-provider 
relationship by affecting communication during the clinical encounter. Providers 
knowledgeable about a patient’s culture may be better able to clearly explain medical 
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diagnoses, and a patient with a sense of shared experience may be more likely to trust 
their provider’s judgment (50). Studies of cross-cultural communication have found, for 
example, that black patients treated by black doctors rated the visits as more participatory 
than when treated by white providers (50). Similar trends have been observed in studies 
of gender concordance where care of a female patient by a female provider is more likely 
to be patient centered (152). However, other research has failed to find significant 
associations between medical care and patient-provider race or sex concordance (153). 
Measures of sex and race concordance have not yet been used to examine unnecessary 
antibiotic prescribing for acute bronchitis. The objective of this study was to examine the 
effect of race and sex concordance with other predictors on prescribing in cases of acute 
bronchitis.  
Methods 
Design  
I used retrospective electronic medical record (EMR) data to identify outpatient visits for 
acute bronchitis at a large, urban safety-net hospital. Visit data on patients and providers 
were abstracted from the EMR via the hospital’s clinical data warehouse. Provider 
characteristics not in the medical record were abstracted from publicly available 
physician profiles. Study staff reviewed the professional headshot, educational history, 
and provider name to assign race. The Boston University Medical Center Institutional 
Review Board approved all study activities.   
Visits 
Visits for acute bronchitis (ICD-9 codes 466.x, 490) conducted between 2008 and 2010 
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in the outpatient clinic by either Family Medicine or General Internal Medicine attending 
physicians were included if the clinician had at least ten visits for RTIs in the dataset. All 
visits included in the study involved patients over 18 years of age.  
Variables 
The primary outcome was the prescription of an antibiotic for an acute bronchitis visit. A 
sample of charts was reviewed to confirm that the ICD-9 diagnosis of bronchitis matched 
the documented clinical indicators. Visits where patients were diagnosed with both acute 
bronchitis and another infection that might warrant an antibiotic were excluded because it 
was unclear which diagnosis was considered in the prescribing decision.  
  The primary independent variables were: 1) race concordance between patient 
and provider and 2) sex concordance between patient and provider. Race was recorded in 
six categories – white, black, Hispanic/Latino, Asian, Middle Eastern or other/unknown. 
Patient race was based on self-report. The EMR combines race and ethnicity, thus 
Hispanic/Latino was included in this category. To determine provider race, a five-person 
panel used a consensus method to assign one of the six racial categories based on a photo 
(154), surname (154, 155), and/or medical school (155). Panel members were given a 
card for each race category to hold up each time they were presented with a photo, 
surname, and school. If there was disagreement, the panel was given the opportunity to 
reach consensus. When consensus could not be reached, race was assigned as 
“other/unknown,” although this only happened in two cases. Provider sex was recorded 
as male or female. 
Other covariates included patient factors — age, sex, health insurance, race, and 
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history of chronic lung or heart disease — and provider factors — age, sex, race, 
specialty (Family vs. General Internal Medicine), and U.S. region of residency training. 
Race and sex covariates reflect only the race and sex of the individual patient or provider 
and are distinct from the concordance variable, which measures the agreement in either 
sex or race between patients and providers.  
Statistical Analysis 
I performed chi-square tests to analyze differences between patient and provider 
characteristics in visits resulting in an antibiotic prescription compared with visits where 
no antibiotic was prescribed. Multivariable regressions were used to examine the 
predictors of antibiotic prescribing. Relative risks from the multivariable model were 
estimated with a binomial complementary log-log (cloglog) model including random 
effects to control for individual provider heterogeneity and to ensure that any findings 
around concordance were not artifacts of individual prescribing practices. Methods of 
estimating the relative risk from the cloglog model are described elsewhere (156).   
I conducted several sensitivity analyses to evaluate model fit. To investigate 
patient complexity, I tested inclusion of the Charlson score (157, 158), and I evaluated 
the effect of including the interaction of race and sex concordance. Sensitivity analyses 
using other regression link functions and using the model with a random subsample of 
1/3 of the dataset further validated the results. Furthermore, I investigated the effect of 
different concordance structures by estimating predicted probabilities of different 
interactions of race and sex concordance for white/nonwhite and male/female pairs 
(Appendix B). This allowed us to investigate whether a particular pairing was 
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disproportionally affecting the results. All analyses were conducted in Stata 13.1. 
Results 
There were 1,177 visits for acute bronchitis included in the study. These 1,177 visits were 
overseen by 70 unique providers. Most visits were among patients who were female and 
non-white (Table 3). The majority of physicians were female and white. Overall, 831 
(71%; 95% CI 68%–73%) visits resulted in an antibiotic prescription. Visits in which 
patients received an antibiotic were more often among patients under 65 years old (72% 
vs. 64% under age 65), female sex (75% vs. 63%), and with a history of lung disease 
(75% vs. 67%) (Table 3.1).  An antibiotic was more often prescribed when the physician 
was female (76% vs. 65%), under age 45 (78% vs. 68%), and a Family Medicine 
provider (84% vs. 67%) compared to visits not ending in a prescription.  
In the adjusted model, visits where the patient and provider shared the same race 
had an 17% lower risk of resulting in an antibiotic prescription compared to visits which 
were not race concordant (RR=0.83, CI 0.75–0.92) (Table 3.1). This result was 
unchanged if Hispanic/Latino patients were excluded. Sex-concordant visits were not 
associated with antibiotic prescriptions (RR=0.94, CI 0.88–1.01). 
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Table 3.1: Risk of prescribing an antibiotic for an acute bronchitis visit 
 
 
Total visits, 
n=1,177 
Prescribed an 
antibiotic  p-value for 
prescribed 
Adjusted risk ratio 
(95% CI)  
  831 (71% of visits) 
  n 
(% of 
visits) n 
(% 
prescribed) 
Race Concordant Visit         
Concordant  454 (38.6) 287 (63.2) <0.01 0.83 (0.75 – 0.92) 
Not concordant  723 (61.4) 544 (75.2)  1.00 (Reference) 
Sex Concordant Visit         
Concordant  725 (61.6) 506 (69.7) 0.44 0.94 (0.88 – 1.01) 
Not concordant  452 (38.4) 325 (71.9)  1.00 (Reference) 
Visit-Level Patient Characteristics        
Sex           
Male 447 (38.0) 281 (62.9) <0.01 0.89 (0.82 – 0.97) 
Female 730 (62.0) 550 (75.3)  1.00 (Reference) 
Age group          
Under 65 years 
old 945 (80.3) 682 (72.2)  1.00 (Reference) 
Over 65 years 
old 232 (19.7) 149 (64.0) 0.02 0.84 (0.70 – 1.02) 
Race*          
White 552 (46.9) 382 (69.3) 
0.52 
1.13 (1.06 – 1.21) 
Black 413 (35.1) 298 (72.2) 
1.00 (Reference) 
Asian/Pacific 
Islander 34 (2.9) 21 (63.6) 
Middle Eastern 8 (0.7) 5 (62.5) 
Hispanic/Latino 170 (14.4) 124 (72.9) 
Insurance          
Commercial 490 (41.6) 335 (68.4) 
0.49 
1.00 (Reference) 
Medicare 306 (26.0) 220 (71.9) 1.06 (0.94 – 1.20) 
Medicaid 277 (23.5) 202 (72.9) 1.00 (0.90 – 1.10) 
Other Insurance 54 (4.6) 41 (75.9) 1.07 (0.93 – 1.22) 
Uninsured 50 (4.3) 33 (66.0) 0.98 (0.87 – 1.11) 
History of Heart 
Disease          
Yes 109 (9.3) 82 (75.2) 0.27 1.13 (1.01 – 1.26) 
No 1,068 (90.7) 749 (70.1)  1.00 (Reference) 
History of Chronic 
Lung Disease          
Yes 550 (46.7) 411 (74.7) <0.01 1.08 (0.98 – 1.18) 
No 627 (53.3) 420 (67.0)  1.00 (Reference) 
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Visit Level Provider Characteristics        
Sex          
Male  587 (49.9) 382 (65.0) <0.01 0.92 (0.76 – 1.10) 
Female 590 (50.1) 449 (76.1)  1.00 (Reference) 
Age group          
Under 45 years 
old 467 (39.7) 366 (78.4) <0.01 0.95 (0.80 – 1.12) 
Over 45 years 
old 710 (60.3) 465 (65.5)  1.00 (Reference) 
Race          
White  821 (69.8) 557 (67.8) <0.01 1.02 (0.81 – 1.28) 
Non-White 356 (30.3) 274 (77.0) 1.00 (Reference) 
Provider Residency 
Training          
Northeast 1,047 (89.0) 741 (70.8) 
<0.01 
1.00 (Reference) 
South 38 (3.2) 35 (92.1) 1.24 (0.99 – 1.57) 
Midwest 76 (6.5) 40 (52.6) 0.90 (0.55 – 1.47) 
West 16 (1.4) 15 (93.8) 1.29 (1.10 – 1.50) 
Specialty of provider          
Family 
Medicine 267 (22.7) 223 (83.5) <0.01 
1.16 (0.97 – 1.38) 
General Internal 
Medicine  910 (77.3) 608 (66.8) 1.00 (Reference) 
*For bivariate and multivariable analyses of race categories were collapsed to white vs. non-white due to 
sample size. 
 
Male patients were less likely to be overprescribed (RR=0.89, 95% CI 0.82–0.97) 
and those with a history of heart disease (RR=1.13, CI 1.01–1.26) or who were white 
(RR=1.13, CI 1.06–1.21) were more likely. There was a higher risk of overprescribing 
(RR=1.29, CI 1.10–1.50) if the visit was conducted by a provider who had completed 
residency in the western U.S., although this result was based on a small sample.  
The results did not substantially change in sensitivity analyses. Because the data 
did not include potentially relevant clinical variables, such as underlying 
immunosuppression, I considered adding a measure which has been used to measure 
patient complexity (158), the Charlson Comorbidity Index (CCI). Inclusion of the CCI 
did not change the results and was insignificant (p=0.3) and was thus excluded. I also 
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tested the effect of being in a visit which was both sex and race concordant. When I 
modeled only the effect of this dual concordance, the concordant visits were less likely to 
end with a prescription (RR=0.84, 95% CI 0.74–0.95). When the model included dual 
concordance as well as the independent effects of race concordance and sex concordance, 
only race concordance was significant (RR=0.87, 95% CI 0.76–1.00). This suggests that 
in the data, any effect of a combined race/sex concordance variable is driven by the 
association between race concordance and prescribing.   
I examined the marginal effects and predicted probabilities from the model to 
investigate the impact of different concordance pairings. Appendix B shows the marginal 
effects of each variable in the cloglog model and confirmed the findings above that race 
concordance had the largest single effect with a marginal effect seven times larger than 
sex concordance. Complementary with the overall results, both white/white and 
nonwhite/nonwhite concordance pairs had a lower predicted prescribing prevalence. The 
predicted probabilities presented some evidence that prescribing is higher when the 
patient is white and the provider is non-white compared to the reverse form of racial 
discordance. The predicted probability of receiving a prescription for a white patient with 
a non-white provider was 77% and 90% depending on the gender of the dyad compared 
to a range of 61% to 77% for a non-white patient and white provider (Appendix B).  
Discussion 
The study demonstrated that race concordance between patient and provider was 
associated with more appropriate antibiotic prescribing. I found that for acute bronchitis 
visits where the provider and patient were of the same race, providers were 17% less 
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likely to prescribe an antibiotic prescription. I did not find a significant relationship for 
sex concordance. Previous studies have focused on the relationship between either 
provider factors or patient factors and unnecessary prescribing (54). To my knowledge, 
sex and race-concordance have never been used in an explanatory model of antibiotic 
prescribing, and the results of this study suggest that further concordance research would 
be fruitful.  
While past research has suggested that patient-provider communication may be an 
important area of focus, there is no consensus on the area of communication that is 
weakest or the best way to improve it (151). Some authors suggest that cross-cultural 
communication can affect prescribing (50). This is particularly important in urban safety-
net medical centers, which often serve racially diverse and socioeconomically 
disadvantaged populations who may experience disparities in care (159). My analysis is 
not able to determine how, exactly, concordance affects the probability of receiving a 
prescription. It could be that a provider was less able to convince a non-concordant 
patient that antibiotics were unnecessary because he or she could not culturally connect 
with the patient. Or perhaps patients are more likely to trust, and take advice from, 
providers with whom they feel a sense of shared identity. Future research should consider 
employing strategies identified in studies on health care disparity, including cross-
cultural communication and awareness, to better understand the dynamics of the patient-
provider relationship in prescribing.  
The study has several limitations. Race data were not collected directly from 
physicians. It is possible several providers were misclassified, affecting the results. 
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However, previous research has demonstrated strong agreement between observed and 
self-reported race (160). Hispanic/Latino origin is an important cultural variable, but is 
difficult to estimate with clinical records or via visual inspection so some Hispanic/Latino 
providers may not have been included. After excluding patients who identified as 
Hispanic/Latino the results were unchanged, but further research is important to evaluate 
potential variations in care. The study was limited by the data available in the EMR, so 
some important variables were excluded, such as duration of symptoms or 
immunosuppression, which may be important. Identification of bronchitis relied on ICD-
9 codes in the medical record, which may be imperfect. A sample of chart reviews 
confirmed ICD-9 coding accuracy and past research suggests that these codes reliably 
identified bronchitis (161).  
In conclusion, patient-provider race concordance predicted antibiotic prescribing. 
While gender concordance was not significant, the direction was the same and it may 
prove significant in a larger study. Race concordance is not the only aspect of the patient-
provider relationship, but it may measure elements important to that relationship such as 
cultural competency, patient-centered explanations of care, or trust. The findings can be 
used to inform efforts to improve antimicrobial stewardship interventions, which to date 
have had limited success and have largely focused on provider knowledge and behavior 
(151). Interventions directed towards the patient have been less frequent and often are 
limited to provision of informational materials (151). Future research should explore the 
mechanisms behind the effect of patient-provider race concordance, perhaps through 
qualitative interviews of patient/provider dyads. Non-clinical indicators such as race and 
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sex concordance may enhance our understanding of how to combat overprescribing and 
inform the design of future interventions. 
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CHAPTER FOUR: THE EFFECT OF OVERPRESCRIBING IN CHILDREN ON 
FUTURE BRONCHITIS VISITS AND PRESCRIBING  
 
Summary 
Many studies of unnecessary antibiotic prescribing do not extend beyond the act of 
prescribing. These studies are important, but leave out a critical part of the prescribing 
process: how overprescribing affects future antibiotic use. In this chapter I evaluate the 
final step in the prescribing sequence: the consequences of prescribing, bolded in Figure 
4.1. The long-term public health consequences of overprescribing, such as resistance, are 
well studied. But an important consequence is how overprescribing might affect future 
behavior of patients, which will be the focus of this chapter. If a patient unnecessarily 
receives an antibiotic, that patient may believe an antibiotic is always required for the 
same set of symptoms, and will come to expect it.  
Conditions framing the 
prescribing decision 
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Consequences 
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Figure 4.1: Conceptual domains of Chapter 4 
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Research question 
This chapter assessed the long-term consequences of overprescribing by studying how a 
provider’s decision to prescribe antibiotics at a child’s first encounter for acute bronchitis 
affects the likelihood of a future encounter and prescription. 
Background 
In the United States, antibiotics are overprescribed to children with viral RTIs 
contributing to ten million unnecessary prescriptions per year (72, 162). Those 
unnecessary antibiotics contribute to antimicrobial resistance and can result in drug-
related adverse events such as diarrhea or Clostridium difficile (138, 163). Early 
antibiotic exposure has been linked to later development of asthma and obesity (82, 164). 
Previous literature has extensively reviewed how a variety of patient, provider, and 
practice characteristics affect prescribing – particularly unnecessary antibiotic prescribing 
- for viral RTI (24, 38) – but the prescribing process is complex and overprescribing 
remains high (24). New ways of looking at the prescribing process are necessary to better 
understand the drivers of overprescribing. 
 Health care providers identify patient expectation for antibiotics as one of the 
major drivers of prescribing (39, 90, 98). However, there is little literature on how 
patients come to expect antibiotics. Parents often seek outside advice when it comes to 
the health of their children, and often follow the advice of their doctor. In this case, early 
childhood medical visits may be formative – the first few visits communicate to the 
parent and child what the “right” answer is. If a child is given antibiotics for bronchitis 
the first time he or she is diagnosed, the parent may expect the same treatment at 
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subsequent visits. This may suggest targeted interventions during early medical 
interactions could have substantial downstream implications for lifetime antibiotic 
exposure. This study describes patient, provider, and practice factors associated with 
early childhood prescribing for privately insured children and explores how early 
prescribing behavior affects longer-term antibiotic and health care utilization including 
future acute bronchitis visits and prescribing.  
Methods 
Study sample 
The analytic sample was constructed using data from the Truven Health Analytics 
MarketScan Commercial Claims and Encounters databases (MarketScan) of 2008–2013. 
MarketScan includes medical claims data from over 100 employer sponsored health care 
plans across the United States for patients aged 0 to 64 and is a yearly cross-section of 
insured employees and their dependents. Individuals are followed longitudinally for as 
long as they are enrolled in a participating health care plan. These claims data are linked 
to an individual who is tracked over time and the dataset is statistically de-identified. The 
database includes inpatient, outpatient, and pharmaceutical claims and identifies the date 
of service, characteristics about the facility providing the service, and a host of financial 
variables such as patient copayment amount. The Boston University Institutional Review 
board ruled this study “not human subjects research” and exempt from review.  
 To examine long-term outcomes I created a cohort of children who had a visit for 
acute bronchitis (ICD-9 codes 466.x, 490) at some point during their enrollment. All of 
the children were born in 2008 and followed through 2013. Of the 420,975 unique 
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children born in 2008, 48,031 had a diagnosis of acute bronchitis and 24,210 were 
enrolled continuously through the end of the study period, 2013. 
Analysis 1: characterizing antibiotic use 
 The first objective of this study was to characterize antibiotic prescribing in the 
entire sample of children with at least one acute bronchitis episode in order to better 
understand what patient, provider, and practice characteristics are most important in 
predicting prescribing. 
Dependent variable 
 The dependent variable for the first analysis was whether or not the child received 
an antibiotic at his or her first episode for acute bronchitis. Consistent with what has been 
done in other studies of antibiotic prescribing, an episode of care is the two week period 
following the initial visit for acute bronchitis where any subsequent visits for the same 
diagnosis are part of the same episode (93), and if an antibiotic prescription was picked 
up within four days of a visit, it was attributed to that visit (24). Antibiotics included in 
the analysis are listed in Appendix C. 
Independent variables 
Independent variables included patient, provider, and facility characteristics found 
to be important in previous literature (see Chapter 1). In children I controlled for sex, age, 
geographic region where they sought care (Northeastern, Midwestern, Southern, or 
Western United States), whether they sought care in an urban environment (identified by 
Metropolitan Statistical Area, or MSA), and type of private insurance including health 
maintenance organizations (HMO), preferred provider organizations (PPO), point-of-
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service (POS) and other (which can include high deductible health care plans, exclusive 
provider organizations, consumer-driven health plans, comprehensive plans, and 
basic/major medical plans – see Appendix C for full definition of each plan type). 
Because comorbidities in children have been shown to affect prescribing in other research 
(78), I used the medical claims to identify comorbidities present by the time of the 
episode according to a validated coding algorithm for pediatric patients (165). I identified 
the following chronic conditions in the cohort: functional or anatomic asplenia; HIV 
infection; chronic renal failure; malignant neoplasms; solid organ transplant; congenital 
immunodeficiency; diseases of the white blood cells; cochlear implant; chronic heart 
disease; chronic lung disease; diabetes; asthma; neurological disorders; chronic liver 
disease; trisomy 21; neuromuscular disorders; disorders relating to low birthweight. A 
full description of the coding algorithm, which used ICD-9 diagnosis codes, ICD-9 
procedure codes, and current procedural terminology (CPT) codes can be found in 
Appendix C. Provider characteristics include the specialty of the provider (such as 
pediatrician) and practice factors include the site of care (such as a physician’s office) as 
well as factors which may influence a practice such as day of the week (a facility with 
less weekend staff may be more likely to prescribe on weekends) and season of the year 
(RTI visits during flu season may be more likely to be attributed to the flu and less likely 
to receive an antibiotic). 
Analysis plan 
To understand the differences between children who were and were not 
prescribed antibiotics for acute bronchitis I used a three step process: (1) I presented the 
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descriptive statistics summarizing the characteristics in children that did and did not 
receive antibiotics; (2) conducted bivariate analysis to assess the differences between the 
groups, and; (3) constructed a predictive model of antibiotic prescription using 
multivariable methods and assessed the quality of the predictive model with goodness-of-
fit statistics.  
 In the first step, descriptive statistics were generated for all variables stratified by 
prescribing outcome of the first episode. For categorical variables such as sex and 
insurance, the number and percentage of participants falling into each category were 
calculated, and for continuous variables such as age, the mean and standard deviation 
were calculated. Because the data are longitudinal – individual children followed over 
time – variables were assessed at the time of the first bronchitis visit. For example, age is 
the mean age of the cohort at the time of the first acute bronchitis episode.  
 Next, differences in independent variables between those receiving and not 
receiving antibiotics were assessed in bivariate analysis. For categorical variables such as 
geography and sex, chi-square analysis was used. If any group had a low cell count 
(under five), Fisher’s exact test was used instead, and any variable with a cell size of one 
or fewer was excluded from further analysis due to sample size. For continuous variables 
I used the student’s t-test, unless non-normality was detected, in which case the non-
parametric Wilcoxin-Mann-Whitney test was used. Differences were considered 
significant if the test statistic yielded a p-value less than 0.05.  
 The dependent variable was whether or not an antibiotic was prescribed – a 
dichotomous variable. Because the dependent variable is binary I used standard logistic 
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regression to examine associations in the multivariable analysis. I assessed the 
appropriateness of the logistic model by evaluating multicollinearity with the variance 
inflation factor (VIF) and the fit of the model via the c-statistic. The VIF assessment of 
multicollinearity determines the extent of linear dependencies among the variables and is 
a product of a linear regression; however, VIF is still frequently used in the logistic 
setting (166). Due to the size of the data set, some frequently used statistics, such as the 
Hosmer-Lemeshow test, are inappropriate (167), so I relied on other post-hoc analyses to 
indicate whether the logistic model was the correct model to use. I also conducted 
sensitivity analyses using other distributional and link assumptions and compare the 
estimated coefficients. I used several goodness of fit measures to evaluate model fit. 
Analysis 2: assessing the long-term effect of early prescribing 
 The second objective was to define early prescribing behavior and test its effect 
on future visits for acute bronchitis and antibiotic prescribing for a subsequent acute 
bronchitis episode of care.  
Dependent variables 
The primary dependent variable for this analysis was whether or not the child 
returned for an additional acute bronchitis episode. To be a distinct episode, the child 
must have had a visit with a primary acute bronchitis diagnosis 14 days or more after the 
first episode, and an episode is defined as in the first analysis (93). The secondary 
dependent variable was whether children with a second acute bronchitis episode were 
prescribed an antibiotic.  
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Independent variables 
The main independent variable was the prescribing behavior at the first acute 
bronchitis episode. This was characterized by six possible behaviors depending on 
whether the child had more than 
one acute bronchitis visit in the 
same encounter (Table 4.1). If a 
child had one acute bronchitis 
visit and did not have a repeat 
visit for the same encounter, the child was either prescribed or not prescribed at that first 
visit. If the child had a repeat  
visit within 14 days, they were categorized in one of four ways: the provider “doubled 
down” on antibiotics, prescribing them for both the index visit and the repeat visit; the 
provider initially did not prescribe an antibiotic but then “gave in” and prescribed on the 
repeat visit; the provider was “steadfast” and did not prescribe for either visit; or the 
prescriber is “one and done,” giving an antibiotic the first time but not the second. 
Other independent variables controlled for patient, provider, and practice 
characteristics and are described in Analysis 1. An additional variable was the length of 
time, in months, between the first acute bronchitis episode and the second (for those with 
two). This controlled for the fact that the likelihood of prescribing might differ depending 
on the last episode – e.g. perhaps providers are less likely to prescribe for a child who 
was seen just three months ago for the same condition. 
 
Table 4.1: Prescribing behaviors 
 Antibiotic, 
first visit 
Antibiotic, 
repeat visit 
“Double down” Yes Yes 
“Give in” No Yes 
“Steadfast” No No 
“One and done” Yes No 
One visit, prescribed Yes - 
One visit, not prescribed No - 
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Analysis plan 
 I examined the effect of early prescribing behaviors on future acute bronchitis 
visits and prescribing in two steps: First, I tested the association between the six 
prescribing behaviors in the first episode of care and whether a child returned for an 
additional visit for acute bronchitis. Second, among children with a second care episode 
for acute bronchitis, I evaluated whether the prescribing behavior from the first episode 
predicted whether or not an antibiotic was prescribed in the second.  
I used logistic regression to test the association between early prescribing 
behaviors and whether a child had a second episode for acute bronchitis (a dichotomous 
variable). I assessed the multivariable model by evaluating multicollinearity and the fit of 
the model via the c-statistic and other post-hoc goodness of fit measures. Sensitivity 
analyses tested other distributional and link assumptions as well as a cross-tabulation 
analysis between prescribing in the first and second episode.  
Similar methods were used to test the association between early prescribing 
behaviors and whether or not a child was prescribed at the second episode. I used a 
multivariable logistic model to predict prescribing at the second episode in the subsample 
of children who returned for a second episode, and performed the goodness of fit 
measures described above. The distributional and link assumptions were varied in 
sensitivity analysis and evaluated with the modified Park and Pregibon link tests. 
Results 
Characteristics of the study sample 
 
Figure 4.2 describes the derivation of the analytic sample. From the data, I 
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identified 48,031 unique children who were born in 2008. Of those, 24,210 were enrolled 
in the dataset through December 31st 2013, had at least one acute bronchitis episode of 
care, and had prescription drug coverage through their insurer the entire time. Five 
thousand, two hundred ninety-nine of these children had a repeat visit for the same 
episode of care within 14 days of the initial bronchitis diagnosis. 247 of these children 
were prescribed an antibiotic both times, putting them in the “double down” category; 
2,892 had a provider who “gave in” and were prescribed an antibiotic on the repeat visit  
 
after not having one on the first; 636 providers were “steadfast,” prescribing neither 
initially or at the repeat visit, and; 1,452 children were prescribed an antibiotic initially, 
but “one was enough” and they were not prescribed on the second. 78% (18,981) of 
Children born in 2008 
with a bronchitis visit...  
48,031 
...continuously enrolled 
through 2013... 
24,210 
...who did not have a 
repeat visit 
18,981 
...and were 
prescribed 
10,665 
....and were not 
prescribed 
8,316 
...who had a repeat 
visit within 14 days... 
5,229 
....were prescribed 
the first visit... 
1,699 
....and the 
second (Double 
Down) 
247 
...and not the 
second (One's 
Enough) 
1,452 
...were not prescribed the 
first visit... 
3,530 
...but were the 
second  
(Give In) 
2,894 
...or on the 
second 
(Steadfast) 
636 
Figure 4.2: The final analytic sample of the first acute bronchitis episode  At	least	one	prescription	 No	prescription 
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children did not have a repeat visit during their first acute bronchitis episode. Fifty-six 
percent (10,665 children) of these were prescribed on this first visit, 44% (8,316) were 
not.  
Analysis 1: predicting antibiotic use 
 The first step of the analysis was to evaluate the differences between children who 
received an antibiotic during their first episode of care for acute bronchitis and those who 
did not. Table 4.2 shows the characteristics and bivariate comparisons of children who 
did and did not receive an antibiotic during their first visit. The unadjusted p-value for the 
bivariate analysis of each variable is also given in the same table. Overall, 12,364 
children received an antibiotic for the first episode of acute bronchitis care – 51% of the 
total sample. Based on the bivariate analysis, those who were prescribed an antibiotic 
tended to be almost a year older (2. years vs. 1.2 years, p<0.001), more often female 
(47% of this group was female vs. 42%, p<0.001), enrolled in a PPO plan (51% vs. 48%, 
p<0.001), lived in the South and Midwest (45% vs. 42% and 23% vs. 22%, respectively, 
p<0.001), and more often came from a rural area (14% vs 12%, p<0.001). Many 
comorbidities were rare, but the prevalence of several was significantly different between 
the two groups. Those who received an antibiotic for acute bronchitis less often had a 
diagnosis of chronic heart disease (2% vs. 3%, p<0.001), chronic lung disease (1.0% vs 
1.4%), asthma (3.1% vs. 2.7%, p<0.001), or disorders relating to low birthweight (9% vs. 
11%, p<0.001) at the time of the episode compared to those who did not receive an 
antibiotic. Those who had their appointment during winter (46% vs. 53%, p<0.001) were 
prescribed less often. Children prescribed an antibiotic more often saw a family medicine 
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provider (13% vs. 7%, p<0.001) and almost always had their appointments in an office 
setting (91% vs. 86%, p<0.001).  
Table 4.2: Children born in 2008 with at least one bronchitis episode 
 
Total Sample 
24,210 
No Antibiotic 
11,846 
Antibiotic  
12,364 
Bivariate 
 p-value 
 
n % (SD) n % (SD) n % (SD) 
 Antibiotic given at first 
bronchitis episode 12,264 51% 0 0% 12,364 100%  
Patient characteristics 
  
  
    Age at first visit mean, SD 1.7 1.4 1.2 1.6 2.0 1.5 <0.001 
Sex 
  
  
    Male 13,359 55% 6,452 58% 6,907 53% <0.001 
Female 10,851 45% 4,758 42% 6093 47% 
Health plan type 
  
  
    PPO 12,072 50% 5,408 48% 6,664 51% 
<0.001 HMO 6,999 29% 3,449 31% 3,550 27% 
POS 3,361 14% 1,551 14% 1,810 14% 
Other 1,778 7% 802 7% 976 8% 
Region 
  
  
    Northeast 2,902 12% 1,498 13% 1,404 11% 
<0.001 
Midwest 5,572 23% 2,521 22% 3,051 23% 
South 10,562 44% 4,747 42% 5,815 45% 
West 4,755 20% 2,222 20% 2,533 20% 
Unknown 419 2% 222 2% 197 2% 
Urban area (MSA)        
Live in MSA 21,085 87% 9,898 88% 11,187 86% <0.001 
Do not live in MSA 3,125 13% 1,312 12% 1,813 14% 
Comorbidities at first episode 
 
  
    Functional or anatomic 
asplenia 28 0% 16 0% 12 0% 0.250 
HIV** 1 0% 1 0% 0 0% 0.463 
Chronic renal failure 27 0% 12 0% 15 0% 0.846 
Malignant neoplasms 18 0% 11 0% 7 0% 0.208 
Solid organ transplant** 3 0% 2 0% 1 0% 0.600 
Congenital 
immunodeficiency* 16 0% 5 0% 11 0% 0.317 
Diseases of the white 
blood cells 31 0% 14 0% 17 0% 1.000 
Cochlear implant** 1 0% 0 0% 1 0% 1.000 
Chronic heart disease 634 3% 338 3% 296 2% <0.001 
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Chronic lung disease  288 1% 164 1% 124 1% <0.001 
Uncomplicated diabetes* 11 0% 7 0% 4 0% 0.366 
Asthma 706 3% 298 3% 408 3% 0.027 
Neurological disorder** 0 0% 0 0% 0 0% - 
Chronic liver disease* 8 0% 6 0% 2 0% 0.156 
Trisomy 21 37 0% 25 0% 12 0% 0.009 
Neuromuscular disorders 239 1% 109 1% 130 1% 0.828 
Disorders relating to low 
birthweight 2,414 10% 1,272 11% 1,142 9% <0.001 
Calendar attributes 
  
  
    Season 
  
  
    Spring  5,086 21% 2,291 20% 2,795 22% 
<0.001 Summer 1,906 8% 736 7% 1,170 9% 
Fall 5,249 22% 2,195 20% 3,054 23% 
Winter 11,969 49% 5,988 53% 5,981 46% 
Day of the week 
  
  
    Monday 5,506 23% 2,471 22% 3,035 23% 
0.024 Tuesday–Thursday  11,545 48% 5,424 48% 6,121 47% 
Friday 3,980 16% 1,878 17% 1,996 16% 
Weekend 3,179 13% 1,437 13% 1,742 13% 
Provider characteristics 
  
  
    Provider specialty at first 
bronchitis visit 
  
  
    Pediatrician 15,890 66% 7,753 69% 8,137 63% 
<0.001 Family medicine 2,472 10% 786 7% 1,686 13% 
ER/Urgent care 776 3% 413 4% 363 3% 
Other 5,072 21% 2,258 20% 2,814 22% 
Practice characteristics 
  
  
    Location of first bronchitis 
visit 
  
  
    Physician office 21,550 89% 9,677 86% 11,873 91% 
<0.001 
Outpatient hospital 1,607 7% 957 9% 650 5% 
ER/Urgent care 607 3% 254 2% 353 3% 
Inpatient  228 1% 167 1% 61 0% 
Other 218 1% 155 1% 63 0% 
Percentage columns for categorical variables display the standard deviation for continuous variables 
*Used Fisher's exact test 
**Excluded from future analyses due to sample size 
Next, I created a predictive model of antibiotic prescribing as a function of 
patient, provider, and practice characteristics. Table 4.3 presents the results of the logistic 
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model. I found that older children (OR = 1.60, p<0.001), females (OR = 1.08, p=0.004), 
and those living in the Midwest (OR = 1.19, p=<0.001), South (OR = 1.31, p<0.001), or 
West (OR = 1.14, p=0.004) had higher odds of being prescribed while those living in an 
urban area (OR = 0.89, P<0.001) had lower odds of being prescribed an antibiotic at their 
first visit compared to the reference group. In general, children with comorbidities were 
less likely to receive an antibiotic. I found many comorbidities predicted a child to be less 
likely to be prescribed, included chronic lung disease (OR = 0.73, p=0.004), asthma (OR 
= 0.76, p=0.002), trisomy 21 (OR = 0.36, p=0.006), and disorders relating to low 
birthweight (OR = 0.82, p<0.001). In adjusting for season, I found that visits in summer 
had a higher odds of resulting in a prescription (OR = 1.18, p<0.001) while visits in the 
winter had lower odds of yielding a prescription (OR = 0.87, p<0.001) compared to visits 
during fall. Compared to coming in for a visit between Tuesday and Thursday, visits 
occurring on a Monday or over the weekend had higher odds of ending with a 
prescription (OR = 1.12, p=0.003 and OR = 1.18, p<0.001, respectively). Relative to 
being seen by a pediatrician, visits conducted by family medicine providers or by other 
non-pediatrician and non-ER doctors had higher odds of ending in a prescription (OR = 
1.71, p<0.001 and OR = 1.34, p<0.001, respectively). Finally, all visits conducted outside 
of a physician’s office, including visits in an outpatient hospital, an ER or urgent care 
center, an inpatient admission, or others, had significantly lower odds of resulting in a 
prescription (OR = 0.48, 0.77, 0.37. and 0.27, respectively, p<0.001 for all).  
 Several tests indicated the model fit well. The c-statistic (0.70) indicates the 
model performs reasonably well and the omnibus F-test for significance results in a p-
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value < 0.001. Because Hosmer-Lemshow was inappropriate, I evaluated the fit with an 
alternative suggested in the literature: the standardized Pearson goodness-of-fit test (168). 
The immense size of the dataset precludes the use of this computationally intensive test 
as is. However, I was able to run the program using a random sample of my data (10,000 
observations), and the resulting standardized Pearson p-value was over 0.05, indicating 
failure to reject the null of good model fit. Also due to large sample size, the Modified 
Park and Pregibon link tests failed to identify one of the major distribution or link 
families as correct. Rather than using uninterpretable link and distribution assumptions in 
order to perfectly fit the data, I used the most intuitive choice with a binary outcome: the 
logistic model. The binomial distribution and logit link had the lowest (albeit still 
significant) test statistics, indicating that among other easily interpretable model 
specification, logistic was preferred. The VIF was less than three for all variables, and 
less than two for most, indicating multicollinearity is low and none of our variables were 
redundant.   
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Table 4.3: Multivariable model predicting antibiotic prescribing 
 
Estimate Odds Ratio 
95% Confidence 
Interval p-value 
Patient characteristics 
      Age at visit  0.468 1.60 (1.56 – 1.63) <0.001 
Sex 
      Male Reference group 
Female 0.082 1.09 (1.03 – 1.15) 0.004 
Health plan types 
      PPO Reference group 
HMO -0.105 0.90 (0.84 – 0.96) 0.002 
POS 0.022 1.02 (0.94 – 1.11) 0.736 
Other 0.005 1.01 (0.90 – 1.12) 0.920 
Regions 
      Northeast Reference group 
Midwest 0.170 1.19 (1.08 – 1.31) <0.001 
South 0.271 1.31 (1.20 – 1.43) <0.001 
West 0.131 1.14 (1.03 – 1.26) 0.004 
Unknown -0.080 0.92 (0.74 – 1.15) 0.338 
Urban area (MSA) -0.115 0.89 (0.82 – 0.97) <0.001 
Comorbidities at any time 
      Functional or anatomic asplenia -0.416 0.66 (0.30 – 1.46) 0.449 
Chronic renal failure 0.205 1.23 (0.54 – 2.79) 0.701 
Malignant neoplasms -0.804 0.45 (0.16 – 1.26) 0.167 
Congenital immunodeficiency 0.583 1.79 (0.56 – 5.75) 0.270 
Diseases of the white blood cells -0.015 0.99 (0.45 – 2.18) 0.869 
Chronic heart disease -0.152 0.86 (0.72 – 1.02) 0.173 
Chronic lung disease  -0.310 0.73 (0.56 – 0.95) 0.004 
Uncomplicated diabetes* -1.186 0.31 (0.08 – 1.16) 0.109 
Asthma -0.275 0.76 (0.64 – 0.90) 0.002 
Chronic liver disease* -0.959 0.38 (0.07 – 2.08) 0.338 
Trisomy 21 -1.011 0.36 (0.17 – 0.77) 0.006 
Neuromuscular disorders -0.141 0.87 (0.66 – 1.14) 0.626 
Disorders relating to low birthweight -0.201 0.82 (0.75 – 0.90) <0.001 
Calendar attributes 
      Season 
      Spring  -0.019 0.98 (0.90 – 1.07) 0.598 
Summer 0.163 1.18 (1.05 – 1.32) <0.001 
Fall Reference group 
Winter -0.134 0.87 (0.82 – 0.94) <0.001 
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Day of the week 
      Monday 0.112 1.12 (1.05 – 1.20) 0.003 
Tuesday–Thursday  Reference group 
Friday 0.037 1.04 (0.96 – 1.12) 0.411 
Weekend 0.165 1.18 (1.08 – 1.29) <0.001 
Provider characteristics 
      Provider specialty at first bronchitis visit 
      Pediatrician Reference group 
Family medicine 0.537 1.71 (1.55 – 1.89) <0.001 
ER/Urgent care 0.161 1.18 (0.98 – 1.41) 0.066 
Other 0.296 1.34 (1.24 – 1.45) <0.001 
Practice characteristics 
      Location of first bronchitis visit 
      Physician office Reference group 
Outpatient hospital -0.735 0.48 (0.42 – 0.55) <0.001 
ER/Urgent care -0.263 0.77 (0.64 – 0.93) <0.001 
Inpatient  -1.000 0.37 (0.27 – 0.50) <0.001 
Other -1.308 0.27 (0.20 – 0.37) <0.001 
 
Analysis 2: Predicting long-term outcomes 
An overview of the two outcomes stratified by prescribing at the time of the first episode 
is presented in Table 4.4. The majority (18,981, 78%) of children only had one episode 
for acute bronchitis, and of those 10,665 (56%) were prescribed an antibiotic and 8,316 
(44%) were not. 5,229 children (28%) had a repeat visit for the same episode of care. Of 
those who had a repeat visit, the majority (2,894, 55%) had a provider who “gave in,” and 
received an antibiotic at the repeat visit. One thousand four-hundred and fifty-two 
children received an antibiotic initially but not at their repeat visit while 636 children 
with providers were “steadfast” and did not receive an antibiotic for either the first or 
repeat visit during the 1st episode of care. 247 children received an antibiotic on both the 
initial and repeat visit. 
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Table 4.4: Prescribing behavior and subsequent acute bronchitis visits and prescribing 
1st episode prescribing 
n 
Rx 
First 
Visit 
Rx 
Repeat 
Returned for 2nd 
episode 
Prescribed  
2nd episode  
 n 
% (of 
total) n 
% (of 
returned) 
"Double down" 247 Yes Yes 157 64% 111 71% 
"Give in" 2,894 No Yes 1,587 55% 695 44% 
"Steadfast" 636 No No 367 58% 196 53% 
"One's enough" 1,452 Yes No 834 57% 514 62% 
One visit, prescribed 10,665 Yes - 4,592 43% 3,415 74% 
One visit, not prescribed 8,316 No - 3,764 45% 2,005 53% 	
The proportion of children returning for a second episode of care for acute 
bronchitis differed across the groups, as did the proportion of those who returned who 
were prescribed. Those in the “double down” category most often returned for a 2nd 
episode of care, with 64% of them doing so, followed by “steadfast” (58%), “one’s 
enough” (57%), “give in” (55%), “one visit, not prescribed” (45%), and “one visit, 
prescribed” (43%). Among those who had a second episode of care, 74% of the “one 
visit, prescribed” group were given an antibiotic followed by “double down” (71%), 
“one’s enough” (62%), “steadfast” (53%), “one visit, not prescribed” (53%), and “give 
in” (44%).  
 To determine the association between prescribing behavior during the first 
episode of care and experiencing a second acute bronchitis care episode I conducted a 
multivariable logistic regression controlling for patient, provider, and practice 
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characteristics (Table 4.5). Compared to children whose first acute bronchitis episode 
consisted of one visit, which resulted in an antibiotic, those with providers who “doubled 
down” or thought “one’s enough” at the first episode had higher odds of experiencing a 
second acute bronchitis episode (OR = 2.01, p<0.001 and OR = 1.29, p<0.001, 
respectively). Those in “give in” and “one visit, not prescribed” groups had lower odds of 
a second episode (OR = 0.90, p=0.022 and OR = 0.75, p<0.001). Having a “steadfast” 
provider at the first episode was not significantly associated with experiencing a second 
episode. 
 Multiple patient, provider, and practice characteristics were also associated with 
experiencing a second acute bronchitis episode. Children with lower odds of experiencing 
a second episode were older (OR = 0.61, p<0.001), female (OR = 0.94, p=0.004), 
enrolled in an HMO (OR = 0.88, p<0.001), lived in an urban area (OR = 0.79, p<0.001), 
and sought care in the spring (OR = 0.80, p<0.001) or winter (OR = 0.70, p<0.001). 
Those living in the south or west had higher odds of experiencing a second episode (OR 
= 1.44, p<0.001 and OR = 1.15, p=0.008). Several comorbidities are also associated with 
higher odds of a second episode, namely chronic heart disease (OR = 1.23, p=0.022), 
chronic lung disease (OR=1.79, p<0.001), asthma (OR = 1.25, p=0.009), and disorders 
related to low birthweight (OR = 1.20, p<0.001).  
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Table 4.5: Multivariable model predicting a 2nd acute bronchitis episode 
 
Estimate Odds Ratio 
95% Confidence 
Interval p-value 
Patient characteristics 
      Prescribing types (ref one visit, prescribed) 
     Double Down 0.698 2.01 (1.52 – 2.66) <0.001 
Steadfast 0.098 1.10 (0.93 – 1.31) 0.257 
Give in -0.107 0.90 (0.82 – 0.99) 0.022 
One's Enough 0.256 1.29 (1.15 – 1.45) <0.001 
One visit, not prescribed -0.283 0.75 (0.71 – 0.80) <0.001 
One visit, prescribed Reference group 
Age at visit  -0.503 0.61 (0.59 – 0.62) <0.001 
Sex 
      Male Reference group 
Female -0.062 0.94 (0.89 – 0.99) 0.004 
Health plan types 
      PPO Reference group 
HMO -0.131 0.88 (0.82 – 0.94) <0.001 
POS 0.011 1.01 (0.93 – 1.10) 0.788 
Other 0.010 1.01 (0.91 – 1.12) 0.854 
Regions 
      Northeast Reference group 
Midwest 0.030 1.03 (0.94 – 1.14) 0.548 
South 0.363 1.44 (1.32 – 1.57) <0.001 
West 0.137 1.15 (1.04 – 1.27) 0.008 
Unknown -0.021 0.98 (0.79 – 1.22) 0.848 
Urban area (MSA) -0.234 0.79 (0.73 – 0.86) <0.001 
Comorbidities at any time 
      Functional or anatomic asplenia 0.155 1.17 (0.52 – 2.61) 0.707 
Chronic renal failure 0.325 1.38 (0.60 – 3.17) 0.442 
Malignant neoplasms -0.364 0.70 (0.24 – 1.99) 0.497 
Congenital immunodeficiency -0.570 0.57 (0.18 – 1.83) 0.341 
Diseases of the white blood cells 0.058 1.06 (0.48 – 2.33) 0.886 
Chronic heart disease 0.205 1.23 (1.03 – 1.46) 0.022 
Chronic lung disease  0.580 1.79 (1.37 – 2.33) <0.001 
Uncomplicated diabetes -0.825 0.44 (0.10 – 1.84) 0.259 
Asthma 0.224 1.25 (1.06 – 1.48) 0.009 
Chronic liver disease 1.822 6.19 (0.74 – 51.71) 0.093 
Trisomy 21 0.082 1.09 (0.54 – 2.19) 0.819 
Neuromuscular disorders 0.028 1.03 (0.78 – 1.36) 0.845 
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Disorders relating to low birthweight 0.180 1.20 (1.09 – 1.31) <0.001 
Calendar attributes 
      Season 
      Spring  -0.224 0.80 (0.74 – 0.87) <0.001 
Summer -0.088 0.92 (0.82 – 1.03) 0.125 
Fall Reference group 
Winter -0.357 0.70 (0.65 – 0.75) <0.001 
Day of the week 
      Monday 0.008 1.01 (0.94 – 1.08) 0.815 
Tuesday–Thursday  Reference group 
Friday 0.031 1.03 (0.96 – 1.11) 0.428 
Weekend -0.078 0.93 (0.85 – 1.01) 0.077 
Provider characteristics 
      Provider specialty at first bronchitis visit 
      Pediatrician Reference group 
Family medicine 0.136 1.15 (1.04 – 1.26) 0.005 
ER/Urgent care 0.039 1.04 (0.87 – 1.25) 0.676 
Other 0.063 1.07 (0.99 – 1.15) 0.107 
Practice characteristics 
      Location of first bronchitis visit 
      Physician office Reference group 
Outpatient hospital -0.167 0.85 (0.74 – 0.96) 0.011 
ER/Urgent care -0.228 0.80 (0.66 – 0.96) 0.018 
Inpatient  0.009 1.01 (0.76 – 1.34) 0.951 
Other 0.246 1.28 (0.96 – 1.71) 0.097 
 
Next, I used logistic regression to explore the association between prescribing 
behavior at the first episode of care and whether or not an antibiotic was prescribed 
during the second episode. Table 4.6 presents the results of this analysis. Children who 
had only one visit during the first episode and were prescribed during that visit had the 
highest odds of being prescribed at the second episode. Compared to that group, the 
“steadfast” (OR = 0.51, p<0.001), “give in” (OR = 0.36, p<0.001), “one’s enough” (OR = 
0.66, p<0.001), and “one visit, not prescribed” (OR = 0.45, p<0.001) categories had 
significantly lower odds of receiving a prescription at the second acute bronchitis 
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episode. Children who were in the “double down” category did not have significantly 
different odds of being prescribed compared to the reference group (p=0.958).  
 Several other factors predicted whether a child received a prescription at the 
second acute bronchitis episode. Children who were covered by a HMO insurance plan 
(OR = 0.90, p=0.046) or who lived in an urban area (OR = 0.87, p=0.026) were less 
likely to be prescribed at the second episode, while those living in the south (OR = 1.17, 
p=0.028) or west (OR = 1.19, p=0.039) had higher odds of being prescribed. Three 
chronic conditions were associated with being prescribed, with a diagnosis of malignant 
neoplasms (OR = 0.13, p=0.030) and chronic heart disease (OR = 0.75, p=0.016) 
associated with lower odds of receiving a prescription and a diagnosis of chronic lung 
disease (OR = 1.26, p=0.003) associated with higher odds. Seeking care during the winter 
was associated with lower odds of a prescription compared to the fall (OR = 0.82, 
p<0.001) and children were more likely to be prescribed if they sought care on a Monday 
compared to mid-week (OR = 1.22, p<0.001). Provider and practice characteristics were 
also associated with whether or not a child was prescribed. Children seen by family 
medicine (OR = 1.42, p<0.001) and other providers (OR = 1.13, p=0.049) had higher 
odds of being prescribed compared to children seen by pediatricians, and being seen 
outside of a physician’s office was associated with lower odds of being prescribed. This 
included being seen in an outpatient hospital (OR = 0.53, p<0.001), an ER or urgent care 
center (OR = 0.71, p=0.002), an inpatient facility (OR = 0.24, p<0.001), or some other 
non-office based location (OR = 0.23, p<0.001).  
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Table 4.6: Multivariable model predicting prescribing at the 2nd acute bronchitis episode 
 
Estimate Odds Ratio 
95% Confidence 
Interval p-value 
Patient characteristics 
      Prescribing types (ref one visit, prescribed) 
     Double Down -0.010 0.99 (0.69 – 1.43) 0.958 
Steadfast -0.666 0.51 (0.41 – 0.65) <0.001 
Give in -1.021 0.36 (0.32 – 0.41) <0.001 
One's Enough -0.410 0.66 (0.56 – 0.78) <0.001 
One visit, not prescribed -0.803 0.45 (0.41 – 0.50) <0.001 
One visit, prescribed  Reference group 
Months since 1st episode 0.018 1.02 (1.01 – 1.02) <0.001 
Age at visit  0.232 1.26 (1.21 – 1.32) <0.001 
Sex 
      Male Reference group 
Female 0.051 1.05 (0.97 – 1.14) 0.233 
Health plan types 
      PPO Reference group 
HMO -0.101 0.90 (0.82 – 1.00) 0.046 
POS 0.062 1.06 (0.94 – 1.21) 0.337 
Other 0.011 1.01 (0.86 – 1.19) 0.896 
Regions 
      Northeast Reference group 
Midwest 0.099 1.10 (0.95 – 1.29) 0.210 
South 0.155 1.17 (1.02 – 1.34) 0.028 
West 0.170 1.19 (1.01 – 1.39) 0.039 
Unknown -1.259 0.28 (0.13 – 0.65) 0.003 
Urban area (MSA) -0.138 0.87 (0.77 – 0.98) 0.026 
Comorbidities at any time 
      Functional or anatomic asplenia 0.007 1.01 (0.38 – 2.70) 0.989 
Chronic renal failure 0.257 1.29 (0.41 – 4.09) 0.662 
Malignant neoplasms -2.036 0.13 (0.02 – 0.82) 0.030 
Congenital immunodeficiency 1.134 3.11 (0.77 – 12.50) 0.110 
Diseases of the white blood cells 1.337 3.81 (0.97 – 15.02) 0.056 
Chronic heart disease -0.289 0.75 (0.59 – 0.95) 0.016 
Chronic lung disease  0.231 1.26 (1.08 – 1.47) 0.003 
Uncomplicated diabetes* - - - - - - 
Asthma -0.131 0.88 (0.76 – 1.02) 0.081 
Chronic liver disease -0.647 0.52 (0.09 – 3.07) 0.474 
Trisomy 21 0.527 1.69 (0.66 – 4.33) 0.271 
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Neuromuscular disorders -0.139 0.87 (0.61 – 1.24) 0.435 
Disorders relating to low birthweight -0.043 0.96 (0.84 – 1.09) 0.524 
Calendar attributes 
      Season 
      Spring  -0.110 0.90 (0.80 – 1.01) 0.071 
Summer 0.040 1.04 (0.89 – 1.22) 0.624 
Fall Reference group 
Winter -0.196 0.82 (0.74 – 0.92) <0.001 
Day of the week 
      Monday 0.199 1.22 (1.10 – 1.36) <0.001 
Tuesday–Thursday  Reference group 
Friday -0.097 0.91 (0.81 – 1.02) 0.101 
Weekend 0.132 1.14 (1.00 – 1.31) 0.056 
Provider characteristics 
      Provider specialty at first bronchitis visit 
      Pediatrician Reference group 
Family medicine 0.352 1.42 (1.23 – 1.65) <0.001 
ER/Urgent care 0.173 1.19 (0.81 – 1.75) 0.379 
Other 0.125 1.13 (1.00 – 1.28) 0.049 
Practice characteristics 
      Location of first bronchitis visit 
      Physician office Reference group 
Outpatient hospital -0.628 0.53 (0.44 – 0.65) <0.001 
ER/Urgent care -0.344 0.71 (0.57 – 0.89) 0.002 
Inpatient  -1.443 0.24 (0.16 – 0.34) <0.001 
Other -1.458 0.23 (0.19 – 0.29) <0.001 
*Inestimable due to small sample size 
       
Goodness-of-fit and sensitivity analyses indicated the model fit well. Both models 
had a good c-statistic: 0.68 for the prediction of the second episode and 0.74 predicting 
an antibiotic prescription at the second visit. The omnibus F-test was significant for both 
models as well with p<0.001, and the Pearson test using a subsample of the data failed to 
reject the null of a good fitting model in both cases. Both models were also free of serious 
multicollinearity issues with inflations factors under three in the VIF analysis. As in the 
first analysis, I selected the most intuitive distribution and link assumptions for the data – 
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the logit distribution with log link. Cross-tabulation of the prescribing behavior is 
available in Appendix C. 
Discussion 
In this chapter I created a predictive model of antibiotic prescribing for acute bronchitis 
in children and assessed how early prescribing experience affected later resource use 
related to acute bronchitis and antibiotics. In this first analysis, I determined what factors 
predicted an antibiotic prescription at the time of the initial visit, and next examined how 
the initial encounter predicted subsequent visits and prescribing.  
In the first analysis predicting prescribing for the first episode of acute bronchitis 
care, the results underscored the importance of including characteristics from the child, 
the doctor, and the health care setting when modeling antibiotic prescribing. First, the 
characteristics of the children significantly affected their odds of being prescribed. 
Similar to other studies of patient factors and prescribing, I found that sex and geography 
were significantly associated with the odds of being prescribed, with females and those 
from the south and west more likely to receive an antibiotic (60, 71) and those from 
urban areas were less likely. Each additional year of life was significantly predictive of 
being prescribed with one of the largest estimated coefficients, which is consistent with 
past literature (56), despite the fact that symptom expression is often similar across age 
groups and guidelines are often the same (59, 169). This could be because older children 
may be able to more clearly communicate symptoms, which the provider uses to justify 
antibiotics. It also may be that providers are less worried about some of the negative 
effects of prescribing (such as diarrhea) in older children (21).  
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Next, the current health state of the child was also an important factor determining 
whether or not he or she was prescribed. The association between comorbidities and 
prescribing was found to be different from some previous studies, and may be related to 
the way that comorbidities were included in the study. While other research has indicated 
that antibiotics and asthma medication are often prescribed together as a “just in case” 
measure (78), my results suggest that asthma is protective against an antibiotic 
prescription. In the multivariable analysis, I measured the effect of having a confirmed 
comorbidity before the acute bronchitis episode. In this case, it may be that doctors who 
are aware of a comorbid condition both see the patient more often to manage the chronic 
condition and attribute some of the symptoms to the conditions (especially for respiratory 
conditions such as asthma and chronic lung disease) instead of to a possible bacterial 
infection requiring an antibiotic. Additionally, because the observed episodes are for 
children with a primary diagnosis of acute bronchitis, it is possible that prescribing for 
asthma is occurring in visits with a primary asthma diagnosis, and this offsets the 
“protective” effect I observe. More research to understand why these conditions are 
protective against prescribing for acute bronchitis would be valuable.  
I also found that provider and practice characteristics were significantly 
associated with prescribing at the first episode. The results show that pediatricians are 
significantly less likely to prescribe antibiotics for acute bronchitis than family medicine 
providers. This phenomenon of elevated antibiotic prescribing practices in family 
medicine has been observed in other research (24) and future interventions may benefit 
from exploring what in the family medicine setting is so different from pediatrics or 
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general internal medicine and may be related to overprescribing. The site of care is also 
important in the prescribing decision, and has implications for where interventions might 
most productively be placed. While the doctor’s office was where most visits occurred, 
every other location of care resulted in lower odds of prescribing. This could be because 
other locations may be differently structured (perhaps the office environment is more 
relaxed when it comes to prescribing whereas an urgent care center may have a rigid 
guideline concordant standard operating procedure) or may simply have different 
priorities regarding stewardship. This may suggest promoting stewardship across a 
medical care setting could be important for promoting proper antibiotic use. 
 In my novel analysis of early prescribing behaviors I found that a child’s first 
interaction with the health care system for acute bronchitis affects whether that child 
returns for a subsequent episode and whether he or she is prescribed. Children who 
received one or two antibiotics for their first acute bronchitis episode were more likely to 
have a visit for a second episode, even after controlling for the health of the child and 
other confounders. Those with two prescriptions at the first visit had more than twice the 
odds of experiencing a second episode compared to those in the “one visit, prescribed” 
category while those who had just one visit and were not prescribed had 0.75 times the 
odds. This could reflect parenting styles – parents who brought a child in more than once 
within 14 days for acute bronchitis may have be more likely to interact with the health 
care system overall. However, other children with two visits in the first episode – those in 
the “steadfast” and “give in” categories – did not have elevated odds of returning for a 
second episode, suggesting that the type of prescribing during the first episode is 
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important for predicting future behavior. However, among those with a second episode, 
most prescribing categories, with the exception of the “double down” category, were 
associated with a lower odds of prescribing at that second episode compared to those in 
the “one visit, prescribed” category. It could be that a patient with multiple visits for their 
first episode of acute bronchitis raised a red flag for providers as possible antibiotic 
seeking patients or it could be that patients who were prescribed an antibiotic with just 
one visit in the first episode of care were more likely to be prescribed in the future if they 
felt the prescribed antibiotic “worked.”  
 The characteristics of the child, his or her comorbidities, and provider and 
practice characteristics were all associated with experiencing a second acute bronchitis 
episode and being prescribed at that second episode. Being insured by an HMO was 
associated with lower odds of experiencing a second episode and being prescribed at that 
episode. Other studies have found that among commercial plans, HMOs are associated 
with lower medical costs which can be due in part to fewer visits and fewer prescriptions 
(170). Those who lived in the south and west were also more likely to experience a 
second acute bronchitis episode and be prescribed at that episode, while those in urban 
areas were less likely. Regional variation has been a topic of study for some time in 
health services research (62), and it is possible the differences I observed could be due to 
patient health literacy, which tends to be lower in the Southeast (75), or simply due to 
differences in local practice which have evolved over time.  
All statistically significant comorbidities were associated with increased odds of 
experiencing a second acute bronchitis episode. It could be that children with comorbid 
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conditions are more connected with the health care system overall, so are more likely to 
seek care for all symptoms. The two comorbidities that predicted a second episode most 
strongly were chronic lung disease and asthma, which could indicate children with a 
history of respiratory diagnoses may be more likely to seek care for respiratory 
symptoms. Chronic lung disease was also associated with higher odds of receiving an 
antibiotic at the second episode, which could be related to clinician uncertainty of 
whether to attribute the symptoms to acute bronchitis or another more serious condition 
associated with chronic lung disease (171). 
Provider and practice characteristics of the first episode affected the probability of 
experiencing a second episode and may be related to the experience or education a patient 
receives at a visit. For example, family medicine providers may allocate limited 
appointment time differently than pediatricians and emphasize antibiotic stewardship 
less, which may in turn affect whether or not a parent brings in a child with acute 
bronchitis symptoms. During the second episode, the provider and practice factors 
predicting prescribing are similar to those factors predicting prescribing for the first 
episode. As in previous literature, family medicine providers are most likely to prescribe 
(24) and there is substantial heterogeneity in prescribing based on location of care.  
This study has several limitations. While MarketScan is a large cohort that allows 
for longitudinal observation, only children covered by private insurance are included in 
the dataset. Previous research has found that overprescribing does not vary between 
public and private insurance (24, 25), but early prescribing experience may be different 
among those covered by public insurance such as Medicaid. While the sample may not be 
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representative of the entire population, other research has shown MarketScan to be a 
fairly good representation of the U.S. privately insured population (172). Additionally, 
the data did not contain information on race/ethnicity which Chapter 1 of this dissertation 
suggested was important in the prescribing decision. The analysis was also constrained 
by the amount of follow-up. First, this study would have benefitted from longer follow-
up to examine how childhood prescribing experiences translated to adult behavior, 
although data of this type are extraordinarily rare. Next, administrative claims do not 
allow me to know exactly why the provider was prescribing the antibiotic. I only 
included visits where acute bronchitis was the primary diagnosis to reduce this bias as 
much as possible, but it is possible that the provider was acting on a different diagnosis 
when he or she wrote the prescription. Finally, I only included children fully enrolled 
from birth through the end of 2013, and children who were not enrolled during the whole 
period may be different. It is possible that this loss to follow-up was differential – e.g. 
perhaps the parents move often so frequently change insurance, and this frequent change 
of settings affects the relationship with the medical system and thus prescribing 
outcomes. While future research into patterns of care for children who come in and out of 
insurance coverage is important to understand that population, it was beyond the scope of 
this research, which was a detailed exploration into how early experiences affect 
subsequent health care visits and prescribing. 
Overprescribing is persistent and difficult to combat. A major challenge is that the 
prescribing process is poorly understood, and that there has been little research into how 
early prescribing can affect a patient’s “antibiotic trajectory.” The goal of this study was 
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to explore whether early antibiotic prescribing affected future visits for acute bronchitis 
and prescribing. I found that early prescribing behaviors are significantly associated with 
future episodes of acute bronchitis care and future prescribing. This novel study into the 
effect of early prescribing serves both as a way to better understand the prescribing and to 
caution potential prescribers of the consequences a simple antibiotic prescription can 
have. Future research should compare this result to an adult population to investigate 
which population’s future utilization is more strongly predicted by prior utilization. The 
unintended effect on future prescribing and health care visits (including the risks 
associated with future elevated exposure to antibiotics) is another compelling piece of 
evidence for stakeholders to leverage in the fight against unnecessary antibiotic use.  
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CHAPTER FIVE: CONCLUSION 
In 2015, President Obama issued the National Action Plan for Combating Antibiotic-
Resistant Bacteria (173) in order to “ris[e] to the challenge of antibiotic resistance and 
potentially sav[e] thousands of lives” (174). However, even as concerns about the threat 
of resistance reach the highest levels of political power, overprescribing remains woefully 
common. To rise to the challenge of resistance, it is critical that researchers investigate 
prescribing and stewardship with innovative methods and measures and from 
perspectives not considered before. The goals of this dissertation were to understand the 
prescribing process in a more comprehensive way in order to promote judicious antibiotic 
use and to better understand how stewardship functions by soliciting the attitudes of 
current infectious disease fellows. Throughout this dissertation, the factors I found to be 
most relevant to prescribing, such as race concordance and how children are prescribed 
following their first acute bronchitis diagnosis, are often absent from the literature and 
thus absent from discussions on crafting policy and interventions.  
Qualitative interviews with infectious disease fellows revealed that there are many 
different ways stewardship works “on the ground.” While these future stewards 
appreciated the importance of stewardship, they considered some stewardship tasks, such 
as carrying an antibiotic pager, to be less effective forms of stewardship compared to 
consulting one-on-one with other providers. This is an important insight into crafting 
effective interventions. Successfully implementing an intervention requires buy-in from 
those who will carry out the intervention. For example, infectious disease fellows are 
often strong advocates of stewardship, but have to balance any intervention to improve 
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stewardship with existing responsibilities. Non-physicians, such as clinical pharmacists, 
may help manage stewardship responsibilities, and the group of fellows I interviewed 
identified pharmacists as critical members of the team. This existing system of support, 
already well integrated in the stewardship process, is a potential resource to promote 
stewardship. The fellows I spoke with were often drawn to infectious disease as a 
“cerebral” specialty, and many thought educating other providers and working together to 
promote proper use of antibiotics was one of the most satisfying and effective 
stewardship activities. Harnessing this enthusiasm by creating interventions that work 
with stewards and emphasize the types of stewardship they know to be most effective is 
an approach that warrants additional study.  
My in-depth study of adult patients diagnosed with acute bronchitis at a large 
academic medical center found that racial concordance between the patient and provider 
plays an important role in whether or not antibiotics are prescribed for acute bronchitis, 
typically a viral RTI where antibiotics are not indicated. After controlling for other 
patient, provider, practice, and clinical factors, whether or not patients and providers were 
race concordant was one of the strongest predictors of whether or not an antibiotic would 
be prescribed. Innovative measure such as race and gender concordance are often left out 
of similar analyses, and this analysis suggests that exclusion is detrimental, and the 
persistence of high rates of overprescribing indicates that there is a need for innovative 
explanatory models to better understand prescribing. Prescribing is the result of a meeting 
between provider and patient, and new measures of how patients and providers interact 
provide much needed insight into overprescribing. The importance of racial concordance 
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may reflect the role of cross-cultural communication and the patient-provider 
relationship. The role of cross-cultural communication in prescribing is rarely described 
in the literature, and may provide an opportunity to promote the judicious use of 
antibiotics. Patient centered care emphasizes understanding patients in the “context of 
their own social worlds” (175) and educating providers in the best ways to communicate 
the importance of stewardship may be an important tool in combating overprescribing.  
Finally, I found that the first interaction a child has with the health care system for 
a diagnosis for acute bronchitis has long-lasting impacts. Unnecessary prescribing 
lingers, with children who received antibiotics during their first acute bronchitis episode 
more likely to return for a second episode over five years compared to children not 
prescribed. Examining repeat visits for the same acute bronchitis complaint allowed me 
to further investigate the effect of the decision whether or not to prescribe following the 
first acute bronchitis diagnosis on long-term use, where, for example, children who have 
repeat visits for their first episode are often more likely to return for a second episode but 
are also less likely to be prescribed at the second episode. This suggests that increased 
patient-provider interaction may affect future interactions and may provide an 
opportunity to encourage proper antibiotic use. This study illustrated that whether or not a 
provider prescribes an antibiotic may affect the likelihood that a child receives a future 
prescription for the same complaint, and providers in all settings should be made aware 
that an antibiotic “just this once” can have lasting influence.  
 There is an urgent need to slow the spread of antimicrobial resistance and to 
encourage more judicious use of antibiotics. The recent White House National Action 
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Plan states that the only way to achieve this goal is through cooperation between 
providers, health care leaders, patients, and other antibiotic stakeholders (173). This 
dissertation supports this assessment. Engaging in more comprehensive research that 
includes novel measures of the patient-provider relationship is an important first step in 
understanding the prescribing process. That same comprehensiveness should then carry 
over into interventions, where taking into account the “whole picture” of prescribing and 
engaging patients, providers, and other stakeholders can inform better, more effective 
interventions.  
 This dissertation opens the door for several important areas of future research. 
From my first study, it is clear that more work is needed to understand how fellowship 
programs can continue to attract high quality physicians while promoting stewardship in 
a way that is effective, engaging, and encouraging. Specifically, long-term prospective 
analyses could follow individual providers over time to compare fellowship program 
characteristics’ effects on providers, and more near term analyses could see how 
programmatic changes, such as who carries the pager and when, affected the quality of 
life of fellows. From the second study, I found a strong association between racial 
concordance and appropriateness of prescribing. While I have hypothesized the reasons 
for this association, such as patient education or cross-cultural communication skills, a 
qualitative interview of patient-provider dyads would be better equipped to explore the 
mechanisms behind this effect. Long-term effects of prescribing on behavior is a rich area 
to explore further with longer running longitudinal cohorts. My third study offers 
important results into the first five years of life, but more research covering a longer 
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period, e.g. the first 20 years, would be highly insightful. It is also important to see how 
subsequent prescribing affects behavior among an adult population. This would inform 
researchers thinking of designing interventions as to what kind of “dose-response” to 
expect: in other words, how many times must it be implemented before an intervention 
behavior “sticks” either among patients or providers. The future areas of research 
prompted by this dissertation are critical to developing better and more effective 
interventions in order to curb the overuse of antibiotics. 
 This dissertation is a response to the crisis of antibiotic overprescribing and 
increasing antimicrobial resistance. The three studies described trace prescribing from its 
origin with how providers think about antibiotics through the long-term effects in 
patients. Corresponding to increased focus on patient centered care, each study highlights 
the importance of communication and a willingness to listen, whether it be surgeons and 
infectious disease fellows, patients and providers, or parents and children. Progress in the 
fight against antibiotic resistance will hinge on the ability of researchers to explore 
creative and innovative interventions and on how well we – providers, patients, 
researchers, decision makers – can present a united front against antibiotic 
overprescribing.  	
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APPENDIX A: CHAPTER 2 SUPPLEMENTAL MATERIALS 
States where infectious disease fellows were interviewed. 
	
Participating fellows were enrolled in an infectious disease fellowship program in one of 
the blue states. White states have at least one fellowship program, but no fellows were 
interviewed from these states. Grey states, including Alaska and Hawaii, represent states 
where no infectious disease fellowship programs existed as of 2014.  									
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Semi-structured qualitative interview guide 
	
PRIMARY RESEARCH QUESTION: What is the role of stewardship in your fellowship 
programs and how does it influence your attitudes and beliefs about antibiotic 
prescribing. 
 
Questions (bullet points are examples of possible probes): 
 
1. Tell me about how you came to be in your fellowship 
• Did you seek out stewardship from residency?  
• How interested are you in stewardship-related fellowship activities?  
• What is your main interest?  
 
2. How does stewardship fit in to your fellowship? 
• How has the stewardship component affected your practice?  
• As you think of going out into practice, how will you use the stewardship 
information from your fellowship?  
 
3. Tell me about your involvement with stewardship in your fellowship 
§ Follow with program-specific probes – understand how the program 
teaches/emphasizes stewardship 
o Formal vs. informal  
  
4. What can be improved around antibiotic stewardship in your fellowship program?  
 
5. Why did you do this interview? 
 
6. Is there anything else you think I should know? 
 
7. Demographics 
Demographic Data Collection:  
 
1) What is your gender?  …………………   1  Male 2  Female       3  Other 
 
2) What year are you in the fellowship program? _________________________ 
 
3) How would you describe your race? _________________________________ 
 
4) In what state do you practice?    ____________________________________ 
 
5) In what other settings have you practiced? For how long? 
 
_______________________________________________________________ 
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Recruitment flyer  
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APPENDIX B: CHAPTER 3 SUPPLEMENTAL MATERIALS 
 
Marginal effects after cloglog model 
Marginal effects after cloglog 
    y  = Pr(overprescribed) (predict) 
      = 0.71440143 
       Variable dy/dx S.E. z p 95% CI X (mean) 
race concordant -0.159 0.040 -4.010 0.000 -0.237 -0.081 0.386 
sex concordant -0.021 0.030 -0.710 0.478 -0.079 0.037 0.616 
provider white -0.059 0.035 -1.680 0.093 -0.129 0.010 0.698 
provider > 45 -0.015 0.035 -0.420 0.674 -0.083 0.054 0.603 
South Res. 0.103 0.085 1.220 0.224 -0.063 0.269 0.032 
Midwest Res.  -0.195 0.063 -3.080 0.002 -0.319 -0.071 0.065 
West Res.  0.214 0.079 2.690 0.007 0.058 0.369 0.014 
Family Medicine 0.137 0.036 3.830 0.000 0.067 0.208 0.227 
Male Patient -0.105 0.030 -3.470 0.001 -0.165 -0.046 0.380 
White Patient 0.101 0.037 2.720 0.007 0.028 0.173 0.468 
Medicare 0.059 0.041 1.420 0.155 -0.022 0.140 0.260 
Medicaid -0.027 0.039 -0.710 0.478 -0.103 0.048 0.235 
Other Insurance 0.011 0.066 0.160 0.874 -0.119 0.140 0.046 
Provider Male -0.051 0.035 -1.460 0.144 -0.120 0.018 0.499 
Uninsured  -0.072 0.076 -0.950 0.342 -0.220 0.076 0.042 
MI/CHF 0.059 0.048 1.230 0.219 -0.035 0.152 0.093 
Patient>65 -0.116 0.043 -2.670 0.008 -0.201 -0.031 0.197 
Chronic Lung Disease 0.088 0.028 3.100 0.002 0.032 0.144 0.467 
(*) dy/dx is for discrete change of dummy from 0 to 1 
   
Predicted probabilities 
  Race 
G
en
de
r 
Patient/ Provider White/ White 
Non-White 
/Non-White 
Non-White/ 
White 
White/  
Non-White 
Male/ Male 0.551 0.510 0.609 0.771 
Male/ Female 0.624 0.582 0.683 0.836 
Female/ Female 0.710 0.668 0.766 0.898 
Female/ Male 0.679 0.637 0.737 0.877 
      
		
101 
APPENDIX C: CHAPTER 4 SUPPLEMENTAL MATERIALS 
 
List of included antibiotics  
The table below provides details on the included antibiotics by RedBook-defined 
therapeutic class. 
Therapeutic class and description  
4 Antibiotics, aminoglycosides 
6 Antibiotics, cephalosporin and related 
7 Antibiotics, B-lactam Antibiotics 
9 Antibiotics, erythromycin & macrolide 
10 Antibiotics, penicillins 
11 Antibiotics, tetracyclines 
16 Quinolones 
17 Sulfonamides 
19 Urinary Anti-infectives (only nitrofurantoin) 
20 Anti-infectives (only metronidazole) 
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Definition of health plan types 
Variable Plan type Description  
PPO 
Preferred 
Provider 
Organization 
Patients are incentivized to use preferred providers. Specialists 
can be seen without primary care referral and services are not 
capitated. Patients may seek care outside of the network but will 
incur a financial penalty 
HMO 
Health 
Maintenance 
Organization 
Patients are limited to a list of providers for all non-emergency 
care. Referral from a primary care provider is required to see a 
specialists. All or some services are capitated 
POS Point-of-Service 
Patients are incentivized to use preferred providers with low 
copays or deductibles. Referral from a primary care provider is 
required to see a specialists. Services can be fully, partially, or 
not capitated and patients can see out of network providers with a 
financial penalty  
Other 
Basic/Major 
Medical 
No preferred providers. The basic policy handles the first set of 
charges such as hospital admission with no out of pocket 
charges, after which the major medical plan assumes coverage 
and is associated with a deductible and coinsurance 
Comprehensive Patient can choose any provider and the plan is associated with a deductible and coinsurance  
Exclusive 
Provider 
Organization 
Patients choose from a list of providers and choose a primary 
care physician. Referral is required for specialist care and plan 
payment is not capitated 
Consumer-
Driven Health 
Plan 
PPO with a Health Reimbursement Arrangement (HRA). HRA is 
funded by the employer and ay be used for drug coverage or 
other designated expenses 
High 
Deductible 
Health Plan 
Features a Health Savings Account (HSA). Employee is 100% 
vested in HSA which may be funded by employee or employer. 
HSA is tax advantaged and portable.  
Adapted from the MarketScan User Guide published by Truven Health Analytics (176) 
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Identifying chronic conditions in children 
The ICD-9 diagnosis and procedural codes and CPT codes were used to identify each 
chronic condition. To be considered chronically infected, children needed evidence of 
one of the following in the medical record: (1) ICD-9 codes listed at two or more 
outpatient visits at least seven days apart; (2) one CPT procedure code, or; (3) any code 
listed at an inpatient visit (165). 
  
ICD-9 
Diagnosis 
Code 
ICD-9 
Procedure 
Code 
CPT Code Notes  
Asplenia  282.4 41.5 38100 38120 
 
 
282.5 
 
38102 
  
 
282.6 
    
 
282.7 
    
 
284 
    
 
289.4 
    
 
289.5 
    
 
759.0 
      759.3         
HIV 42 
      V08         
Renal Failure 403 39.27 36800 90989 
 
 
404 39.42 36810 90993 
 
 
581 39.43 36815 90997 
 
 
582 39.95 36818–36821 90999 
 
 
583 54.98 90935 93990 
 
585 
 
90937 90918 
 
 
586 
 
90940 90919–90921 valid 2006–2008 
 
753 
 
90945 90951–90962 valid after 2009 
 
V42.0 
 
90947 
  
 
V45.1 
 
90951–90970 
    V56         
Immunosuppressive  140–172 92.2 
   conditions 174–208 99.25 
   Neoplasms V58.0 
    
 
V58.1 
    
 
V67.1 
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V67.2         
Solid organ trans. V42.81 41.0 38240 
  
 
V42.82 37.5 38241 
  
 
V42.0 33.6 33945 
  
 
V42.1 46.97 33935 
  
 
V42.84 50.59 44135 
  
 
V42.7 33.5 44136 
  
 
V42.6 33.51 47135 
  
 
V42.83 33.52 50360 
  
 
V42.89 55.69 50365 
  
 
V42.9 41.94 38999 
      52.8       
Congenital 279 
    immunodeficiency           
Diseases of WBCs 288.0 
      288.1         
Cochlear 
 
20.96 69930 
  
  
20.97 
       20.98       
Heart Disease 393–398 36.0 33510–33514 
  
 
402 36.1 33516–33519 
  
 
404 36.2 33521–33523 
  
 
410–414 36.3 33530 
  
 
416 
 
33533–36 
  
 
424 
 
92980–82 
  
 
425 
 
92982 
  
 
428 
 
92984 
  
 
429.7 
 
92995 
  
 
745 
 
92996 
  
 
746 
      747.1         
Chronic Lung 277.0 
    
 
416.8 
    
 
416.9 
    
 
490 
    
 
491 
    
 
492 
    
 
494 
    
 
496 
    
 
500–505 
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506.4 
    
 
515 
    
 
516 
    
 
518.83 
    
 
518.84 
      770.7         
Asthma 493         
Diabetes 249 
    
 
250 
    
 
357.2 
    
 
362.0 
    
 
366.41 
    
 
648.0 
      E932.3         
Chronic Liver 571 39.1 37140 37183 
 
 
572 42.91 37145 43204 
 
 
573.0 
 
37160 43205 
 
 
456.0 
 
37180 43243 
 
 
456.1 
 
37181 43244 
 
 
456.2 
 
37182 43400   
Trisomy 21 758.0         
Neuromuscular 333.7 
    
 
343 
    
 
345 
    
 
779.0 
    
 
780.39 
      359         
Low birthweight 765.0 
      765.1         
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 Cross tabulation of prescribing in first and second episode 
 
  Second Episode 
 
  Double 
down 
Steadfast Give 
in 
One's 
enough 
One visit, 
prescribed 
One visit, 
not 
prescribed 
Fi
rs
t E
pi
so
de
 
Double 
down 
n 3 2 7 8 98 39 
Total % 0.03 0.02 0.06 0.07 0.87 0.35 
Row % 1.91 1.27 4.46 5.1 62.42 24.84 
Column 
% 
2.24 0.88 1.09 1.46 1.63 1.05 
Steadfast n 3 8 27 19 166 144 
Total % 0.03 0.07 0.24 0.17 1.47 1.27 
Row % 0.82 2.18 7.36 5.18 45.23 39.24 
Column 
% 
2.24 3.51 4.22 3.47 2.75 3.87 
Give in n 15 35 182 100 545 710 
Total % 0.13 0.31 1.61 0.88 4.82 6.28 
Row % 0.95 2.21 11.47 6.3 34.34 44.74 
Column 
% 
11.19 15.35 28.44 18.25 9.04 19.06 
One's 
enough 
n 14 23 53 61 416 267 
Total % 0.12 0.2 0.47 0.54 3.68 2.36 
Row % 1.68 2.76 6.35 7.31 49.88 32.01 
Column 
% 
10.45 10.09 8.28 11.13 6.9 7.17 
One visit, 
prescribed 
n 66 63 118 204 3082 1059 
Total % 0.58 0.56 1.04 1.81 27.27 9.37 
Row % 1.44 1.37 2.57 4.44 67.12 23.06 
Column 
% 
49.25 27.63 18.44 37.23 51.15 28.43 
One visit, 
not 
prescribed 
n 33 97 253 156 1719 1506 
Total % 0.29 0.86 2.24 1.38 15.21 13.33 
Row % 0.88 2.58 6.72 4.14 45.67 40.01 
Column 
% 
24.63 42.54 39.53 28.47 28.53 40.43 
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